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ABSTRACT 
 
 
Microglia are active sensors of the brain and respond promptly to even minor disturbance in their 
microenvironment. A feature of this response is the accumulation of these cells at the site of lesion. 
Neonatal jaundice is a common condition of the newborn and may determine injury to neurons and 
glial cells, such as microglia, when levels of unconjugated bilirubin (UCB) are excessive.  
With the objective to evaluate whether microglia have a protective or deleterious role, we decided 
to assess, using the Boyden chamber, the chemotactic effect of free unbound UCB (fUCB), as well as 
the migration ability of UCB-treated microglia in the absence or in the presence of chemotatic 
compounds, such as ATP and S100B. Also, we intended to evaluate the effect of 
glycoursodeoxycholic acid (GUDCA) as a modulator. To characterize our usual model of microglia 
isolation, phenotypic evaluation of cultures with different days in vitro (DIV) was performed by 
estimating cell morphology, nuclear factor-kappaB (NF-κB) activation and phagocytic ability. 
We observed that fUCB did not act as a chemotactic compound for microglia and that cells treated 
with UCB showed decreased migration ability. Co-incubation with GUDCA prevented this effect and 
enhanced microglia migration. However, reduced effects were observed in the presence of ATP and 
abolished when using S100B. Isolated microglia with 2 DIV showed features of activation, but 
presentedramified morphology of the “resting” state, less NF-κB activation and increased phagocytosis 
at 13 DIV.  
Data indicate that microoglia exposure to UCB leads to a reduced migration ability and that co-
incubation with GUDCA prevents this deleterious effect, resulting in an increased migration. 
Characterization of microglia phenotypes, along the time in culture, point to 13 DIV cells as the most 
suitable for studies intended to evaluate microglia reactivity to UCB, and probably to other stimuli. 
 
 
Keywords: Unconjugated bilirubin; Microglia morphology; Cell migration; Phagocytosis; Nuclear 
factor-kappaB; Glycoursodeoxycholic acid. 
 
 
 
 
 
 
 
 
 
 
RESUMO 
 
 
Amicroglia são células vigilantes activas, respondendo prontamente à mínima alteração do 
parênquima cerebral, acumulando-se no local de lesão. A icterícia neonatal, frequente no recém-
nascido, pode causar dano nos neurónios e células gliais, como a microglia, quando as 
concentrações de bilirrubina não conjugada (BNC) são excessivas. Tendo por objectivo a avaliação 
do papel protector ou prejudicial da microglia, decidimos determinar, usando a câmara de Boyden, se 
a BNC livre, não ligada à albumina, exercia algum efeito quimiotáctico na microglia, bem como na 
capacidade de migração da microglia tratada com BNC, na presença e na ausência de agentes 
quimiotácticos, como o ATP e o S100B. Pretendeu-se ainda, avaliar se o ácido glico-ursodesoxicólico 
(AGUDC) exercia algum efeito modulador. Para caracterizar o fenótipo da microglia obtida no nosso 
modelo, procedeu-se à caracterização de culturas com diferentes dias in vitro (DIV), através da 
avaliação da morfologia celular, da activação do factor nuclear-kappaB (NF-κB), e da capacidade 
fagocítica. 
Observámos que a BNC livre não exerce quimiotaxia e que a microglia tratada com BNC parece 
estar danificada e ter menos capacidade para migrar, efeito que foi invertido quando co-incubámos as 
células com AGUDC. Contudo, tal efeito foi reduzido na presença de ATP e não se verificou na 
presença de S100B. A microglia mostrou estar activada aos 2 DIV, mas apresentou uma morfologia 
ramificada, característica do estado vigilante, menor activação do NF-κB e aumento da fagocitose, 
quando avaliada aos 13 DIV. 
Os resultados obtidos indicam que a exposição da microglia à BNC leva à perda da sua 
capacidade de migração e que a co-incubação com AGUDC, não só reverte como aumenta a 
migração. A caracterização dos fenótipos da microglia aponta para as culturas de 13 DIV como as 
mais adequadas para estudos que pretendam avaliar a reactividade da micróglia à BNC e 
provavelmente a outro estímulo. 
 
 
Palavras-chave: Bilirubina não-conjugada; Morfologia da microglia; Migração celular; Fagocitose; 
Factor nuclear-kappaB; Ácido glico-ursodeoxicólico 
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I. INTRODUCTION 
 
 
1. Microglia: introduction and overview 
The survival and proper function of neurons is ensured by the large number of glial cells (Streit, 
2002). Among this group of cells, a unique population resembling neural environment-adapted 
macrophages comprises upwards 12% of the non-neuronal brain cells and is designed by microglia 
(Aloisi, 2001; Ladeby et al., 2005). These cells are ubiquitously distributed in non-overlapping 
territories throughout the central nervous system (CNS) including the spinal cord, but they vary in 
density, with the white matter generally containing fewer microglia than the grey matter (Soulet and 
Rivest, 2008; Ransohoff and Perry, 2009). 
Since these cells derive from a mononuclear phagocyte lineage, they share several morphological 
features and functions with macrophages. Thus, microglia constitute the brain’s immune system 
contradicting the initial idea of CNS as an immune privileged site (Kreutzberg, 1996; Streit, 2002). For 
this reason, microglia play an essential role in both physiological and pathological conditions (Polazzi 
and Monti, 2010), as it will be further discussed. 
 
1.1. Microglia phenotypic diversity 
For a long time, microglia phenotypes were solely divided in a resting and an activated state. In 
healthy normal CNS, microglia would be in a resting state presenting small cell soma with rod-shaped 
nuclei and numerous branched processes. In pathological conditions, microglia would turn into an 
activated state undergoing several morphological alterations, like the acquisition of an amoeboid 
shape with processes retraction, upregulation of cell surface markers and production of a plethora of 
bioactive mediators (Kim and de Vellis, 2005; Hanisch and Kettenmann, 2007). Cells in the resting 
state have been for a long time considered to be quiescent and inactive. Also, it was described that 
conversion to an activated state occurred nonspecifically irrespective of the injury, that is, in a 
stereotyped manner with a predetermined program of functions to execute (Davis et al., 1994; 
Gehrmann et al., 1995).  
Recent reports, however, demonstrate that although microglial cell bodies are relatively fixed, their 
fine processes present an elevated motility, higher than that of astrocytes, allowing them to constantly 
palpate and monitor their microenvironment (Davalos et al., 2005; Nimmerjahn et al., 2005). Formation 
of these processes occurs even in absence of any pathogenic stimulus suggesting that this formation 
may be associated with the integration of homeostatic signals throughout the CNS (Raivich, 2005; 
Carson et al., 2007). Thus, these cells are highly active in their presumed resting state and the term 
“surveillant” has been advanced to replace this traditional definition (Ransohoff and Cardona, 2010). 
Furthermore, the activation process is adaptive so that microglia response is specific for each stimulus 
and brain region, and depending on the circumstances, this response may have neuroprotective or 
neurotoxic outcomes. (Carson et al., 2007). For instance, expression of some surface molecules 
associated with immune function show brain regional variation (de Haas et al., 2008).  
Therefore, microglial activation is not a simple on-off switch and the heterogeneity appears to be 
an adaptation to support the diversity of neurons present in CNS (Hanisch and Kettenmann, 2007; 
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Silva et al., 2010). In fact, microglial cells can detect microdamages in their neighborhood and play 
regenerative functions without undergoing a drastic transformation or initiating an inflammatory 
response. However, when stimuli are stronger or prolonged, microglial cells undergo more dramatic 
changes (Hanisch and Kettenmann, 2007). 
Recently, it has been debated the concept of different states of activation of microglia accounting 
for the differing functional properties of these cells (David and Kroner, 2011). The idea emerged from 
research in non-CNS field in an attempt to perceive whether macrophages play a harmful or beneficial 
role after injury and which revealed important insights into macrophage polarization.  Analogous to the 
T helper (TH) 1/ TH2 dichotomy of T cell polarization, macrophages can be polarized by the 
microenvironment to mount specific M1 or M2 functional programs (Porta et al., 2009). Classical (M1) 
activation, induced by interferon (IFN)-γ, is characterized by a robust pro-inflammatory response 
required for the elimination of extracellular pathogens. On the other hand, interleukin (IL)-4 triggers an 
alternative (M2) activation important for the immune response to parasites as well as for tissue repair 
(David and Kroner, 2011; Saijo and Glass, 2011). Since macrophages are innate immune cells, their 
primary function is to act as phagocytes in response to pathogens. Nevertheless, they are capable of 
calling adaptive immune cells, despite the limited ability to process and present antigen to T cells, so 
that both arms of immune response act in concert to restore the homeostasis (Town et al., 2005). 
Curiously, the populations of effector CD4 T cells intervening in the response are determined by 
macrophage polarization. For example, M1 cells release IL-12 that leads to activation of TH1 which, in 
turn, release IFN- γ that induce long-lasting classical activation (Martinez et al., 2009).  
However, these simplified polarization states (M1 and M2) describe a complex process and are 
the extremes of a spectrum of functional states (Mantovani et al., 2004). In fact, subgroups of M2, like 
M2a, M2b and M2c, have been used to further define macrophage polarization, since this general 
designation encompasses cells with dramatic differences in their biochemistry and physiology 
(Gordon, 2003; Mantovani et al., 2007). Furthermore, it has also been proposed a distinct division of 
macrophage populations into three groups based on their homeostatic activities – host defense, 
wound healing and immune regulation (Mosser and Edwards, 2008). 
The transposition of these concepts to microglia is quite simple in the case of classical activation 
and might also be applicable in the case of alternative activation. However, the definition of the 
steady-state in the case of microglia is more challenging and the determinants of this state might be 
very distinct from those imposed to macrophages. Moreover, it is not known if the deactivation of 
microglia results in a state functionally similar to the resting state. Notwithstanding, reports available 
are sufficient evidence to support the association between distinct phenotypes and pathology (Saijo 
and Glass, 2011) 
Therefore, macrophages and microglia recognize signals from  their microenvironment that induce 
specialized activation programs (Martinez et al., 2009) leading to divergent effects in response to CNS 
injury (Kigerl et al., 2009). Thus, depending on their differentiation status, microglia differently affects 
cellular function with either a deleterious or beneficial outcome in the repair (Miron et al., 2011).  
Hence, traditional definition of microglial phenotypes based on classic morphologic studies is now 
being replaced by a definition of functional states (Fig. I. 1). This new definition accounts for 
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differences in activation states undergone by microglia to achieve appropriated effector responses for 
each challenge to CNS (Ransohoff and Cardona, 2010). The recent discovery of microglial 
involvement in neurogenesis, postlesional and “synaptic stripping,” underscores the existence of 
additional, functionally adapted microglial phenotypes (Graeber, 2010).  
 
 
Fig. I. 1: Microglial phenotypic diversity. 
A. Microglial cells show a great phenotypic heterogeneity and plasticity being capable of quickly adaption to 
achieve an appropriated effector response for each challenge to CNS. B. Recently, it was proposed the concept 
of different states of activation, ranging from “classical” activation (or M1) to “alternative” activation (or M2), which 
represent the extremes of a spectrum of functional states. C. Other authors extended the classification into three 
groups based on their homeostatic activities. They are arranged according to the three primary colors, with red 
designating classically activated macrophages, yellow designating wound-healing macrophages and blue 
designating regulatory macrophages. Secondary colors, such as green, purple and orange, represent cells that 
share properties from two of those groups. 
 
Functional and phenotypic heterogeneity of these cells imply that no simple expression signature 
exist for microglia (Graeber and Streit, 2010). Indeed, in uninjured CNS, macrophages and microglia 
in different regions of the brain show differences in morphology and surface markers. This allows 
“resting” microglia to be distinguished from activated macrophages/microglia by their low CD45 
expression, but in the injured CNS, this is no longer possible (David and Kroner, 2011). Therefore, 
along with a new definition, it becomes essencial to seek for new means of identifying this complexity 
of microglial phenotypes. 
 
M2
M1
Classically activated 
macrophages
Wound-healing 
macrophages
Regulatory 
macrophages
B
A
C
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1.2. Role of microglia in critical periods of brain development 
Distribution of microglia in the CNS varies with the different stages of brain development and is 
accompanied by the acquisition of different functions (Cuadros and Navascues, 1998).  The roles of 
microglia during early stages of brain development, namely neonatal/postnatal period, and in aging 
brain are critical for the proper functioning of this organ and determine, in part, the possible 
occurrence of long-term neurological disabilities. Therefore, the next two topics will be intended to 
review these issues. 
 
1.2.1. Early brain development 
The origin of microglia has been at the centre of debate since their first documentation by del Rio-
Hortega (1932) according to whom microglia were derived from the invasion of mesenchymal pial 
elements during embryonic development. Currently, it is generally accepted by most authors that 
these cells derive from progenitors, at the yolk sac, that arrive to the developing CNS through the 
bloodstream, ventricles and meninges, at an early embryonic stage (Imai et al., 1997; Chan et al., 
2007; Bilbo and Schwarz, 2009) (Fig. I. 2). In contrast,other authors still believe that microglia have a 
neuroectodermal origin arguing that neuroectodermal matrix cells are able to differentiate into 
microglia locally (Fedoroff, 1995).  
 
 
Fig. I. 2. Origin of microglial cells. 
Microglial cells originate from primitive progenitors that arise in the yolk sac early during embriogenesis. They 
enter the embryo at the embryonic day (E) 8 and surround the neuroepithelium by E9.5. At E10.5, the earliest 
microglia are found in the brain. Adapted from Ransohoff, 2011 and Saijo, 2011. 
 
There is a “developmental window” during which the microglial progenitors infiltrate into the CNS 
and that extends from embryonic day (E) 10 to E19 in rodents and from the latter half of the first 
trimester and throughout the early part of second trimester in humans (Rezaie and Male, 2002b; 
Rezaie and Male, 2002a). After entering the brain, these precursors originate microglial cells that still 
retain features of their progenitors presenting an amoeboid morphology and being highly motile, 
phagocytic and proliferative (Schlegelmilch et al., 2011). They then migrate by tangential and radial 
migration and proliferate as amoeboid microglia becoming distributed throughout the nervous 
parenchyma (Marín-Teva et al., 1998; Navascues et al., 2000). First appearance of these 
macrophage-like microglia occurs about E14 in rat brain and continues to increase in density reaching 
a peak within the first postnatal week, between postnatal day (P) 4 and P8, with slightly variability 
depending on brain region (Wu et al., 1992; Ling and Wong, 1993). During this time window, 
amoeboid microglia plays a central role in phagocyting cellular debris resulting from apoptosis of 
overproduced neurons (Kim and de Vellis, 2005; Schlegelmilch et al., 2011). Also, even survival and 
neuronal death itself can be regulated in part by microglia through the release of growth factors and 
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cytokines that not only influence neurons but all the other surrounding cells (Kreutzberg, 1996; 
Hanisch, 2002). Indeed, cytokines are involved in many important processes in which microglia are 
committed like neurogenesis, synaptogenesis and gliogenesis (Santambrogio et al., 2001; Nawa and 
Takei, 2006). Later in development, microglial cells also participate in neuritogenesis as well as in 
axonal growth and guidance of neurons (Streit, 2001) and it has also been suggested that they can 
promote vasculogenesis and angiogenesis (Pennell and Streit, 1997). Some of these processes 
extend from embryonic period throughout adolescence or even adulthood (Rice and Barone, 2000). 
When microglia is mainly in an amoeboid/phagocytic state or present solely primitive ramification, 
they can respond promptly to infection or injury (Ling and Wong, 1993; Santos et al., 2008). Indeed, 
several studies report cases of neonatal pathological conditions in which microglia is involved, like 
hypoxic-ischemic injuries (Tahraoui et al., 2001; Kaur and Ling, 2009; Deng et al., 2010) and 
excitotoxic brain damage (Dommergues et al., 2003). In these cases, concomitant to the microglial 
activated phenotype, several surface markers are up-regulated, like major histocompatibility complex 
(MHC) class II and complement receptors (Greensmith and Navarrete, 1994; Ábrahám and Lázár, 
2000). Also, inflammatory transcription machinery starts with nuclear factor-κappaB (NF-κB) activation 
(Nijboer et al., 2008), leading to the release of mediators and modulators of inflammation that 
contribute to  aggravate the pathological condition (Lai and Todd, 2006). Although this is the general 
outcome, some factors can have neuroprotective role following trauma (Ellis et al., 2007; Nijboer et al., 
2008), which will be further discussed. 
Pathologies in the neonatal period can have significant repercussions later in life, since it has 
been demonstrated that they can result in a phenomenon called “glial priming”. In this case cells 
become sensitized by an insult such that subsequent responses to future challenges are exacerbated 
(León-Chávez et al., 2003; Perry et al., 2003) and can lead  to cognitive and behavioral impairments 
(Perry et al., 2002; Nawa and Takei, 2006; Cooke and Abernethy, 2010). It is not without precedent 
that early development exposure to neurotoxic agents may determine latent effects on both 
morphological and behavioral endpoints which are manifest during the aging process (Barone et al., 
1995). Furthermore, it should be noted that the first postnatal weeks are particularly critical due to 
maximal brain growth rate, implying that any alteration will impact on neurogenesis ability and brain 
function in later life (Georg Kuhn and Blomgren, 2011). At about P15 in rodents (and from late second 
to early third trimester in humans), microglia reach their final destination in CNS parenchyma and 
undergo differentiation, a last major process that follows proliferation and migration. This sequence of 
events often referred to as “developmental” plasticity culminates with amoeboid microglial cells lastly 
turning into fully mature, ramified microglia (Bilbo and Schwarz, 2009; Tambuyzer et al., 2009). These 
processes-bearing cells constitute the “resident” microglia of the adult brain. 
 
1.2.2. Aging brain 
The changes that occur in microglia with normal aging of the brain is an issue of great interest 
since it can provide us insights about neurodegenerative disorders to which aging is the major risk 
factor. Aging itself is not considered a disease but it appears to result in increased microglia activation, 
complement factors, inflammatory mediators and brain atrophy (Lucin and Wyss-Coray, 2009). 
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Microglia from aged brain shows amoeboid-like morphology, increased proliferation and antigen 
expression with up-regulation of MHC class II, as well as increase in inflammatory cytokines 
production (Perry et al., 1993; Cagnin et al., 2001). They also showed enhanced proliferation and 
resistance to a down-regulated phenotype, losing the sensibility to the anti-inflammatory cytokine 
transforming growth factor (TGF)-β1 (Rozovsky et al., 1998). However, the chronic use of non-
steroidal anti-inflammatory drugs appears to be effective in treating Alzheimer’s disease (AD) by 
diminishing microglial activation (Mackenzie and Munoz, 1998). This is particularly true if nonsteroidal 
anti-inflammatory drugs are used at the earliest possible times as preventive instead as a recovering 
therapy (Varvel et al., 2009)  
Reactive microglial profile can lead to an exaggerated release of pro-inflammatory cytokines in 
case of activation of innate immune system that may lead to behavioral and cognitive impairments 
(Perry et al., 2003; Cunningham et al., 2005). What triggers increased microglial activation is still 
unclear but oxidative stress, resulting from increased reactive oxygen species (ROS) appear to have a 
determinant role (Floyd and Hensley, 2002; Lu et al., 2004). In fact, gene-expression profile of aged 
human and mouse brains indicates an environment of inflammation and oxidative stress with reduced 
expression of genes related to synaptic function/transport, growth factors and trophic support (Lee et 
al., 2000; Lu et al., 2004). These global changes paint a bleak picture of the aged brain where neurons 
encounter increased challenges and receive reduced support. 
Despite morphological and phenotypic changes indicating microglia activation, it has been 
proposed that microglia may undergo senescence, becoming dystrophic (Streit et al., 2008). The 
morphological changes seen in this case are distinct from the ones that occur during microglia 
activation and include the loss of ramifications and even partial or complete fragmentation of 
cytoplasm, and nuclear condensation (Streit et al., 2004b). This degeneration in normal aging brain 
could explain the high incidence of microglial apoptosis in AD brain reported by Lassmann et al. 
(1995). Dystrophy of microglia may reduce the secretion of neurotrophic factors and downregulate 
phagocytosis. Indeed, older rats reveal less clearance of myelin after a toxin-induced demyelination 
lesion (Zhao et al., 2006). Furthermore, tau pathology was recently associated with dystrophic rather 
than activated microglia supporting the idea that it is the loss of microglial neuroprotection that 
contributes to the onset of sporadic AD (Streit et al., 2009). Once dystrophic microglia accumulates in 
the aging human brain it is assumed that microglia undergo progressive deterioration. 
In conclusion, it is probably the joint action of increased levels of inflammatory mediators and 
diminished levels of neurotrophic functions that lead to neuronal loss and inefficient clearance of toxic 
aggregates in neurodegenerative diseases (Fig. I. 3). 
 
2. Functional roles of microglia 
The most characteristic feature of microglial cells is their activation at a very early stage in 
response to even minor pathological changes in CNS (Kreutzberg, 1996). However, the functions of 
these cells extend beyond this ability, since they have important functional roles even in healthy brain 
(Nakajima and Kohsaka, 1993) (Fig. I. 4). Microglia play essential roles mainly during early brain 
development (as already discussed) and in the onset and progression of neurodegenerative diseases 
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where they can perform protective or toxic functions that will determine the brain functionality in the 
future (Perry et al., 2010). 
 
Fig. I. 3. Microglia in the aged brain. 
During aging, microglial cells can become over-activated or senescent, resulting in increased pro-inflammatory 
response and decreased neuroprotective functions, respectively. Therefore, neurons encounter increased 
challenges and receive reduced support in the aged brain, accounting for neurodegeneration seen during age-
related diseases. 
 
The following sections will be dedicated to discuss the functional roles of microglia both in 
physiological and pathological brain. 
 
 
Fig. I. 4. Functional roles of microglia. 
Resident microglia, when activated, adopt one of many diverse phenotypes and perform their functional roles 
during both healthy brain development and in response to pathological changes. Adapted from Silva, 2010. 
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2.1. Surveillance and repair 
Microglia play a pivotal role in immune surveillance, host defense, and tissue repair, maintaining 
the homeostasis in the CNS (Liu et al., 2001). During CNS development there is an intense 
remodeling in the brain since neurons must be generated in right quantity and location, and neural 
connections have to be properly established. Therefore, formation of mature neural circuits requires 
the elimination of inappropriate synaptic connections, a process termed as pruning. Recently, Stevens 
et al. (2007) demonstrated that the proteins C1q and C3b, both involved in the classical complement 
cascade, are required for this process as deficiencies in one or both proteins lead to defects in 
synapse elimination. This finding points to members of the complement cascade as new immune 
system players with also non-immune functions. The model is based in an early model from Jennings 
(1994) in which unwanted synapses are tagged by C3b and then phagocytosed by the resident 
microglia which express C3 receptor.  
Since microglia appeareed to be involved in synaptic pruning, it  is suggested that they might also 
contribute to plasticity after lesions (Cullheim and Thams, 2007). Indeed, an increased number of 
microglial cells is present both during development of CNS and in neurological diseases, reinforcing 
the idea of microglia involvement in synaptic remodeling in postnatal brain, but also in adult brain 
during pathological scenarios. Blinzinger and Kreutzberg (1968) showed that microglial cells caused 
the displacement of synaptic boutons from injured neurons, a process termed “synaptic stripping”. 
Similar observations have been made where activated microglia migrate and strip synapses during 
inflammatory processes and appear to have neuroprotective consequences (Trapp et al., 2007). In 
fact, there are three ways of synapse modification or elimination that are supposed to be mediated by 
microglia: proteolytic modification of the perisynaptic environment, remodeling of dendritic spine 
morphology, and phagocytic engulfment of dendritic spines, as well as of axon terminals (Tremblay 
and Majewska, 2011). 
 Microglia have also been pointed to induce neuronal apoptosis with the subsequent engulfment of 
cellular debris as demonstrated in cerebellar slice cultures where microglia showed to induce Purkinje 
cell neurons to undergo apoptosis (Marin-Teva et al., 2004), and by a wide set of experiments 
evidencing that apoptotic cells are phagocytosed by microglia (Hume et al., 1983; Perry et al., 1985; 
Streit, 2001). This subject will be further discussed in section 2.2.3. 
Microglia functions are not limited to differentiated cells but also in regulating neural 
stem/progenitor cells during both physiology and pathology. Walton and his colleagues (2006) 
demonstrated that conditioned meda from microglia were able to reconstitute neurogenesis and also 
showed that these cells may suffer alterations in their function with age, becoming more supportive of 
neuronal maturation in adult. Another study showed that in cases of injury to the CNS, activated 
microglia release soluble factors capable of directing migration of precursor cells towards sites of 
injury and also of influencing differentiation towards a neuronal phenotype (Aarum et al., 2003). A role 
for microglia in promoting CNS lesion repair was further supported by studies with presenilin 1 (PS1) 
variants linked to the early-onset familial AD, in which proliferation and neuronal differentiation of 
progenitor cells are significantly impaired and associated with a decrease in the number of activated 
microglia. Furthermore, a different profile of secreted soluble factors was exhibited by microglia from 
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mice expressing the wild-type PS1 or PS1 variants suggesting a role for these factors in mediating 
adult hippocampal neurogenesis (Choi et al., 2008). 
Microglia also appear to exert functions that promote vascularization in the CNS. In an early study 
from Pennell and Streit (1997) it was observed that  neural allografts were colonized by microglial cells 
before any blood vessels formation. Also, they continued to differentiate parallel to graft vascular 
development, and are often seen in close proximity to ingrowing vessels suggesting their participation 
in graft neovascularization. In fact, more recently, microglia were shown to differentiate from myeloid 
progenitors to facilitate vascularization in a model of ischemic retinopathy (Ritter et al., 2006). The 
existence of tumor-associated macrophages (TAMs) with pro-tumoral functions raised the possibility 
that microglia, as brain resident macrophages, could have a role in angiogenesis (Allavena et al., 
2008). However, in this case, the outcome of this response might not be the one desired since TAMs 
produce factors that promote angiogenesis, remodel tissue and dampen the immune response to 
tumors (al-Sarireh and Eremin, 2000). Therefore, this particular case will be addressed later.  
 
2.2. Role in innate and adaptive responses 
Microglia reside in the healthy CNS as surveillant cells and are critically involved with both innate 
and adaptive immune system, regulating inflammation and cell damage in the brain (Chew et al., 
2006). They respond rapidly to changes in the CNS microenvironment and, depending on the 
condition, their response may have neuroprotective or neurotoxic outcomes (Ladeby et al., 2005), as 
already mentioned. 
Activation of microglia involves several features including cell morphological changes, 
upregulation of several cell surface markers, production of inflammatory mediators, as well as the 
ability to present antigens and to perform phagocytosis (Hanisch and Kettenmann, 2007). These 
features do not define one single microglial phenotype per every challenge to CNS, as 
aforementioned. Indeed, Town et al. (2005) consider that exists a continuum of microglial activation, 
with phagocytic response (innate activation) at one end and antigen presenting cell function (adaptive 
activation) at the other. Therefore, the nature and duration of stimuli influences the pathways of gene 
expression  and the phenotypical changes that will occur afterwards, reinforcing the idea of plasticity in 
microglial response (Ransohoff and Perry, 2009; Parkhurst and Gan, 2010). 
 
2.2.1. Signals triggering activation 
Transformation of microglia occurs following infectious diseases, inflammation, trauma, ischemia, 
brain tumors and neurodegeneration (Kreutzberg, 1996). These cells are under strict control of the 
neurochemical environment and its effects are site-specific, accounting for differences in the degree of 
microglia activation and inflammatory reactions in different CNS regions (Aloisi, 2001; Hanisch, 2002).  
The first signal leading to the activation is the separationof microglia from their microenvironment 
inhibitory inputs that maintain them in a steady-state (Ransohoff and Cardona, 2010). In healthy CNS, 
microglia are constitutively restrained by inhibitory influences mainly produced by neurons (Hanisch, 
2002) (Fig. I. 3). One of those signals is mediated through interaction of the fractalkine (CX3CL1), 
released by neurons, with its receptor CX3CR1 expressed on microglia. Ablation of the receptor 
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deregulates microglia responses resulting in neuronal death in vivo, as observed in several models of 
CNS insult (Cardona et al., 2006; Ré and Przedborski, 2006). Interestingly, this function depend on 
cell-to-cell contact but this membrane-tethered chemokine can be cleaved and act as a soluble 
molecule with chemoattractive activity (Chapman et al., 2000), an issue to be discussed in the next 
section. Interaction of the myeloid restricted molecule CD200R with its widely expressed ligand CD200 
is also determinant to block microglia activation (Taylor et al., 2011). Another example of an inhibitory 
signal derives from endogenous ligands of neurons that act on triggering receptor expression by 
myeloid cells-2 (TREM2), promoting phagocytosis and retarding inflammation (Hsieh et al., 2009). 
When neurons are damaged, the communication through these “calming signals” is disrupted leading 
to microglia activation with the consequent increase of inflammatory response and neurotoxicity 
(Cardona et al., 2006; Ré and Przedborski, 2006).  
 
 
Fig. I. 5. Steady-state microglia and homeostasis in the central nervous system (CNS).  
Under steady-state conditions, microglia exhibit an extensively ramified morphology and a resting phenotype. This 
phenotype is maintained in part through neuron-derived signals, including CX3CL1 and CD200, which act through 
corresponding receptors expressed by microglia. Also, functional triggering receptor expressed by myeloid cells-2 
(TREM2) is essential to prevent excessive innate and adaptive immune responses. Disruption of these calming 
signals leads to microglia activation with a switch to a characteristic amoeboid morphology. 
 
Microglia can also detect some factors that can lead to their activation. For example, serum 
constituents crossing the disrupted blood-brain barrier (BBB) (Ransohoff and Perry, 2009), altered 
synaptic activity leading to variations in neurotransmitters availability such as glutamate (Taylor et al., 
2003) and ATP (Davalos et al., 2005), thus resulting in microglia activation. In the case of purine ATP 
that is released by damaged neurons, it acts on microglia to mediate processes extension (Gyoneva 
et al., 2009) and the function of microglia as phagocytes (Koizumi et al., 2007). Plasma fibrinogen can 
also bind to an engaged macrophage receptor 1 (Mac-1) /complement receptor (CR) 3 on activated 
microglia leading to increased phagocytic activity. Several cytokines and colony-stimulating factors 
(CSFs) also induce proliferation or phenotypic and morphological changes consistent with microglial 
activation (Kreutzberg, 1996).  
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In addition to endogenous signals, non-self components like bacterial and viral molecular patterns, 
recognized by toll-like receptors (TLRs) expressed on microglia, also lead to activation of these cells. 
Lipopolysaccharide (LPS), an Gram-negative bacterial endotoxin acting on TLR4, is widely used as an 
experimental activator since by changing microglia morphology and inducing the production of harmful 
factors. Indeed, LPS leads to microglial production of nitric oxide (NO), tumor necrosis factor (TNF)-α 
and IL-1β through the mediation of conventional protein kinase C ((Nakajima et al., 2003).  
 
2.2.2. Motility 
Microglial cells are able to sense extracellular directional cues and to respond with asymmetric 
changes in cell morphology and motility. 
In the healthy brain, “resting” microglia display a baseline motility characterized by the extension 
and retraction of their cellular processes without cell body movement (Davalos et al., 2005; 
Nimmerjahn et al., 2005) but, after CNS injury, they can migrate to rapidly populate the site of injury 
(Morgese et al., 1983).  This movement of microglial cells leading to their accumulation at the site of 
lesion (a process called homing) is essential for the cellular immune responses of microglia and is 
triggered by “find-me” signals released by the damaged tissue (Azuma et al., 2001; Kurpius et al., 
2007). Movement of microglia can be the result of a random, non-vectorial motility (chemokinesis), or 
a directed migration that depends from a chemical gradient to organize the movement (chemotaxis), 
or both (Devreotes and Janetopoulos, 2003; Miller and Stella, 2009).  
Cell migration can be triggered by a diverse array of chemoattractants. Consistent with their role in 
the immune response in the CNS, microglia express an array of receptor for chemokines which are 
involved in the intercellular communication in brain and contribute to intracerebral recruitment of 
immune cells (Aloisi, 2001; Hanisch, 2002; Kim and de Vellis, 2005). Fractalkine, as mentioned in the 
previous section, is a chemokine that can exist in two different forms, membrane-anchored or as a 
soluble glycoprotein (Harrison et al., 1998). Under normal conditions, CX3CL1 is constitutively 
associated to the neuronal membrane, stimulating higher intracellular calcium mobilization in 
responding cells. This  process is apparently needed for adhesion properties.However, after an 
excitotoxic stimulus, the chemokine undergoes a cleavage by matrix metalloproteinases (MMPs) 
triggered by the NMDA (N-methyl-D-aspartate) receptor pathway (Chapman et al., 2000). The soluble 
glycoprotein can then interact with its receptor expressed on microglia inducing their chemotaxis 
(Harrison et al., 1998). Thus, the release of this molecule is an early event in the inflammatory 
response leading to neuronal death after an excitotoxic injury (Chapman et al., 2000). An intriguing 
aspect of the role played by CX3CL1-CX3CR1 pair in this inflammatory response is the fact of having 
different consequences under different pathologic conditions. While several disease models showed 
that CX3CR1 deficiency deregulates microglial responses resulting in neurotoxicity in vivo, in mouse 
cerebral ischemia it is associated with better general recovery and reduced inflammation (Denes et al., 
2008). Moreover, microglial  migration is also induced, among others, by the lymphoid chemokine 
CCL21, which involves chloride channels (Rappert et al., 2002), and by secondary lymphoid-tissue 
(Biber et al., 2001), both expressed by damaged neurons and acting on CXCR3 receptor expressed 
by microglia. 
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Microglial cells also migrate towards neurotrophic factors such as the epidermal growth factor 
(Nolte et al., 1997) and nerve growth factor (De Simone et al., 2007), corroborating the role of 
microglia in brain development. Pathological protein aggregates, such as amyloid-β (Aβ), have also 
been shown to induce microglial migration (Rogers and Lue; Gyoneva et al., 2009). 
Purines that are released from injured tissue in higher levels into the extracellular space by 
neurotransmission, lead to microglia chemotaxis (Parkhurst and Gan, 2010) (Fig. I. 6). Indeed, the 
baseline motility of microglial processes in the intact brain is modulated by some of the ATP signaling 
mechanisms mediating injury-induced microglial responses (Davalos et al., 2005). Until now, process 
extension and migration is known to involve chloride channels (Hines et al., 2009), ATP G protein-
coupled purinergic receptors (P2YR) (Honda et al., 2001; Haynes et al., 2006), outward potassium 
currents (Wu et al., 2007), astrocytic connexin hemichannels (Suadicani et al., 2006), integrin β1 
(Ohsawa et al., 2010), signaling through phosphoinositide 3-kinase, Akt (Irino et al., 2008; Franke et 
al., 2009) and non-transcriptional activation of matrix metalloproteinase-9 (Choi et al., 2010). In fact, 
microglial cells from mice lacking P2Y12R receptor are unable to polarize, migrate or extend processes 
towards nucleotides, either  in vitro or in vivo (Haynes et al., 2006). Besides P2YR, ATP acts on 
ionotropic P2X receptors (P2XR) and P2X4R which are also involved in microglial chemotaxis as 
demonstrated by Ohsawa and his colleagues (2007). Moreover, the P2X7R mediate ATP release, 
essential for amplification of calcium signal transmission within the astrocytic network (Suadicani et al., 
2006). Furthermore, microglial cells themselves can release ATP so that a positive feedback 
mechanism may exist to perpetuate migration. Results from in vitro assays showed that ATP, as well 
as ADP, induce chemotaxis and membrane ruffling, a characteristic structure of migrating cells (Honda 
et al., 2001). To notice that ATP also stimulates chemokinesis, which is independent of a chemical 
gradient (Miller and Stella, 2009). To add that ATP concentration released from  injured cells may not 
be enough to generate a rapid microglial response in all brain pathologies (Davalos et al., 2005). 
Intriguingly, Duan and his co-workers (2009), and more recently Samuels and his colleagues (2010), 
claim that nitric oxide (NO) is the true responsible for directing the movement of microglia after nerve 
injury in leech. According to these studies, ATP released by damaged cells activates microglia and 
induces their initial movement, whereas NO directs migration of the cells to CNS lesions. Indeed, the 
activity of the constitutive endothelial nitric oxide synthase (eNOS) is increased even before microglia 
accumulate, and persists during later stages of this accumulation (Chen et al., 2000). In mammals, 
glial calcium waves, triggered by injury, lead to the release of ATP (Scemes et al., 2007) and NO 
generation (Li et al., 2003), thus indicatingthat theymay work in concert to induce microglia 
chemotaxis. In fact, NO mediates microglial response to acute spinal cord injury in vivo, but this 
process is under the control of ATP (Dibaj et al., 2010). Nucleotide uridine diphosphate (UDP) is  
released by dying neurons and recognized by P2Y6 receptor (P2Y6R), specifically expressed on 
microglia. However, in this case, UDP cause P2Y6 R-dependent phagocytosis in vivo and in vitro. 
Interestingly, ATP is not able to efficiently activate this receptor suggesting that microglia is first 
attracted by this “find-me” signal and subsequently recognizes UDP as an “eat-me” signal leading to 
the engulfment of the target (Inoue, 2007; Koizumi et al., 2007). 
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Another curiousl aspect of this purinergic signaling is its involvement in the retraction of microglia 
processes. Indeed, a switch of the chemotactic response to ATP occurs in activated microglial cells, 
such as the one observed in LPS-pretreated microglia (Gyoneva et al., 2009). This chemorepulsion 
away from ATP is a consequence of upregulation of a G protein-coupled adenosine receptor (AR), 
A2AR, which is activated by adenosine resulting from rapid ATP breakdown by nucleotidases (Orr et 
al., 2009). Also, simultaneously, there is the downregulation of P2Y12R as a result of TLR activation by 
LPS (Gyoneva et al., 2009). Therefore, microglia extend their processes and migrate towards the local 
of lesion where they envelop the area and adopt an amoeboid morphology as the one seen during 
brain neuroinflammation and neurodegeneration. 
 
 
Fig. I. 6. Purinergic signaling involved in microglia motility. 
Presynaptic neuron release ATP as a cotransmitter, by exocytosis. The released ATP acts postsynaptically on 
P2X  and P2Y receptors activated by ADP, UTP and UDP, as well as ATP.  ATP is also released from astrocytes 
(and probably  from microglia, as well) to participate in glial–neuron interactions. Both P2X and P2Y receptor 
subtypes are expressed by astrocytes. Activation of P2Y receptors on astrocytes triggers a calcium (Ca2+) wave 
inducing the release of ATP through connexin hemichannels. P2X4 and P2Y12 receptors expressed on resting 
microglia mediate migration, whereas P2Y6 receptors that are expressed on the activated amoeboid microglia 
mediate phagocytosis of debris at the site of damage.  Also, activated microglia express A2A receptors that are 
activated by adenosine (ADO) resulting from ATP breakdown by ectonucleotidases. Activation of such receptors 
induces chemorepulsion of microglial cells. Not depicted is the activation of potassium and chloride channels as 
well as signaling through phosphoinositide 3-kinase and Akt resulting from activation of P2Y12 receptors. 
 
Another compound with chemoattractive function that was recently described is S100B. This 
protein is abundantly expressed in astrocytes but also in microglia and is released during the course of 
acute and chronic brain disorder (Ellis et al., 2007). Once released, S100B exerts autocrine and 
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paracrine effects mostly by engaging RAGE (receptor for advanced glycation end products) on 
responsive cells. In low concentrations this protein might exert trophic functions, while in high 
concentrations, like those shown to be present in the extracellular milieu in case of brain damage, has 
pro-inflammatory effects leading to activation of microglia, enhancing migration and secretion of pro-
inflammatory mediators (Bianchi et al., 2011). For these reasons, S100B has been suggested to play 
a role in the pathophysiology of neurodegenerative and inflammatory brain diseases (Sorci et al., 
2010). 
The signaling pathways involved in migration are diverse, as described above, and control 
different types of primary microglial cells movement (Miller and Stella, 2009). 
 
2.2.3. Phagocytosis 
Cells can take up macromolecules and particles from the surrounding medium in a process 
termed endocytosis. This is essential for ingestion and uptake of extracellular nutrients, for antigen 
presentation, and for removal of microbial pathogens. During endocytosis cells absorb the material or 
organisms from the extracellular space by engulfing them with their plasma membrane which then 
buds off inside the cell to form a vesicle containing the ingested material. Three principal mechanisms 
of endocytosis have been described. One of the best-characterized endocytic processes is receptor-
mediated endocytosis via clathrin-coated pits. In this case cells internalize molecules by the inward 
budding of plasma membrane vesicles containing proteins with receptor sites specific for the 
compounds. The term pinocytosis refers to the ingestion of dissolved material or single molecules 
from the extracellular space. During this process the cytoplasmic membrane invaginates and pinches 
off small pinocytic vesicles which are then transferred to the cytosol. Phagocytosis is the third form of 
endocytosis involving the vesicular internalization of solid particles, such as microbial pathogens or 
apoptotic cell debris. Binding of the particle to receptors on the surface of the phagocytic cells 
stimulates the extension of pseudopodia, which eventually surround the particle, and fuse to form a 
large intracellular vesicle called phagossome. Once entered into the cell, the phagosome fuses with 
the lysosome, producing phagolysosomes in which the ingested material is digested (Silverstein et al., 
1977; Mukherjee et al., 1997) . 
Phagocytosis is a major function of activated microglia. This function is critical for the uptake and 
degradation of infectious agents and senescent cells, and it participates in development, tissue 
remodeling, immune response, and inflammation (Chew et al., 2006). In general, microglial 
phagocytosis can be divided into two distinct responses: phagocytosis of pathogens and stimulation of 
TLRs inducing a pro-inflammatory cascade (Fig. I. 7A) and clearance of apoptotic cell membranes and 
recognition of phosphatidylserine (PS) residues inducing an anti-inflammatory response (Fig. I. 7B). 
Microglia, as other phagocytic cells, have the capacity to discriminate a large number of potential 
pathogens from self antigenes, utilizing a restricted number of phagocytic receptors. This ability 
derivesfrom the capacity that these receptors have to recognize conserved motifs on pathogens, not 
found in higher eukaryotes, which by having essential roles in the biology of the invading agents, are 
not subjected to high mutation rates. These receptors are collectively termed pattern recognition 
receptors (PRRs), as they recognize specific pathogen-associated molecular patterns (PAMPs) 
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(Janeway, 1992; Aderem and Underhill, 1999). The major PRRs include the Fc receptors (FcRs) and 
the complement receptors (CRs) which recognize immunoglobulins and complement proteins coating 
the particles, acting as opsonins. Besides these, other receptors are involved in particle uptake, such 
as  lectins, like mannose receptor that recognize mannans, other non-complement-receptor integrins 
and scavenger receptors (SR) that recognize surface components on bacteria including LPS(Aderem 
and Underhill, 1999; Underhill and Ozinsky, 2002). Multiple receptors are simultaneously engaged to 
mediate internalization, activate microbial killing, and induce the production of inflammatory cytokines 
and chemokines. Collectively, these cellular processes constitute the phagocyte response. Certain 
phagocytic receptors such as FcRs trigger inflammatory responses directly, whereas others, such as 
complement receptors, often do not stimulate inflammatory responses (Ravetch and Clynes, 1998). In 
many cases, these responses are regulated by additional receptors (that are not themselves 
phagocytic), such as TLRs, which are widely expressed on microglia. During phagocytosis, TLRs are 
recruited to the phagosomes, although recruitment does not require receptors activation (Underhill and 
Ozinsky, 2002). Nevertheless, they can sample the contents to determine the nature of the pathogen 
and participate in the formulation of an inflammatory response appropriate for defense (Aderem and 
Ulevitch, 2000). Also, activation of TLR signaling pathway by bacteria regulate internalization and 
phagosome maturation (Blander and Medzhitov, 2004). Concomitantly, TLRs activate NF-κB (Kawai 
and Akira, 2007) which can transactivate promoters of genes involved in immune and inflammatory 
responses (Baeuerle, 1991). Indeed, TLR4 can mediate LPS-induced macrophage activations of IL-1β 
and IL-6 gene expression, chemotaxis, phagocytosis, and oxidative ability (Wu et al., 2009). 
Microglial cells also play an important role in the recognition and clearance of apoptotic cells. 
Removal of apoptotic cells usually involves three central elements. First, the attraction of phagocytes 
via soluble "find-me" signals released signals by damaged cells, an issue already discussed in 
previous section. Second, recognition and phagocytosis via cell surface-presenting "eat-me" signals 
and finally, suppression or initiation of inflammatory responses depending on additional innate immune 
stimuli (Napoli and Neumann, 2009).  
The best studied “eat-me” signal is PS, which translocates from the inner to the outer leaflet of 
plasma membrane at the early stage of apoptosis. Interestingly, it was recently demonstrated that 
viable cells can also express PS without leading to their phagocytosis indicating that the exposure of 
these residues alone is not sufficient to be recognized by microglia as an “eat-me” signal (Segawa et 
al., 2011). The exposed PS on apoptotic cell is recognized by several phagocyte receptors including a 
presumptive PS receptor (PSR) (Savill et al., 1993), even though experimental demonstration of such 
a receptor has been quite controversial (Williamson and Schlegel, 2002). Recently, several groups 
have identified receptors that both directly recognize PS and induce phagocytosis of apoptotic cells. 
These receptors include the brain-specific angiogenesis factor 1 (Park et al., 2007a), the T-cell 
immunoglobulin domain and mucin domain 4 (Miyanishi et al., 2007; DeKruyff et al., 2010; Freeman et 
al., 2010), and stabilin-2 (Park et al., 2007b). 
Although the mechanisms of recognition of apoptotic cells have not been completely resolved, 
several other molecules appear to be involved, as well. These include the milk fat globule factor-E8 
which act as soluble bridging protein that binds to both the signal on the apoptotic cell and the 
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receptor on the phagocyte, thus acting as a collectin or opsonin (Fuller and Van Eldik, 2008). The 
arrest-specific gene 6 helps phagocytic cells in recognizing surface PS expression and facilitates the 
clearance of PS-expressing cells (Ishimoto et al., 2000). SRs, such as CD36, appear to recognize 
membranes of apoptotic cells which are negatively charged (Husemann et al., 2002) and CRs 
expressed on microglia recognize the complement protein C1q, which is able to bind to PS and act as 
a bridging molecule in apoptotic cell recognition during early stages of apoptosis (Paidassi et al., 
2008). Indeed, both receptors mediate myelin phagocytosis by microglia even though CR3 has a 
dominant role (Reichert and Rotshenker, 2003; Rotshenker, 2003). TREM2 interacts with ligands on 
apoptotic neurons, stimulating their removal and counter-regulating pro-inflammatory signals to allow 
repair (Neumann and Takahashi, 2007; Hsieh et al., 2009).  
Suppression of inflammation during removal of apoptotic cells involves both direct inhibition of pro-
inflammatory cytokine production and release of anti-inflammatory factors, which all contribute to the 
resolution of inflammation. For instance, in acute multiple sclerosis lesions, removal of myelin debris 
by microglia leads to suppression of microglial inflammatory activity with downregulation of 
inflammatory cytokines and chemokines production (Liu et al., 2006). Also, macrophages ingesting 
apoptotic cells showed increased production of TGF-β1, prostaglandin E2 (PGE), platelet-activating 
factor (Fadok et al., 1998) and IL-10 (Zhang et al., 2010). Interestingly, macrophages engulfing 
apoptotic cells release adenosine which triggers A2AR that mediates suppression of inflammation 
(Köröskényi et al., 2011). Moreover, a mechanism dependent on the chemokine receptor CCR2, a 
major chemokine receptor for microglia- and blood-derived monocytes, is involved in the recruitment 
of cells from the bone marrow to limit Aβ plaque load by phagocytosis (Napoli and Neumann, 2009). 
Also in AD, loss of neuron-microglial fractalkine signaling ameliorates the condition that leads to 
reduced deposition of Aβ, by mediating an altered activation and phagocytic ability of these cells (Lee 
et al., 2010). This demonstrates the intimate relation of phagocytosis and chemotaxis properties of 
microglia since, as already discussed, adenosine plays an important role in mediating the retraction of 
microglial processes and acquisition of an amoeboid morphology essential to perform their effector 
functions, such as phagocytosis. Indeed, both processes are actin polymerization-dependent since 
because cytoskeleton reorganization is required for their initiation (Peracino et al., 1998). 
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Fig. I. 7. Phagocytic receptors of microglia.  
Microglia recognize specific structural patterns (PAMPs) of most microbial pathogens via their TLRs, complement 
receptors (CRs), Fc Receptors (FcRs) or scavanger receptors (SRs), leading to a pro-inflammatory response. B.  
Microglia recognize apoptotic cells through phosphatidylserine residues (PS) expressed on the membrane of the 
death cells. These residues are recognized by PS receptors, like Tim4, which are supported via additional 
phagocytic receptors including TREM2. Phagocytosis of apoptotic cells induces the release of anti-inflammatory 
cytokines Adapted from Neumann, 2009 and Napoli, 2009. 
 
In conclusion, phagocytosis is a cell response with important functions in the course of an immune 
response, but also during tissue remodeling and wound healing. However, it is not a cell response that 
occurs as an isolated event, and a phagocytic stimulus triggers, besides associated cell responses of 
destructive nature, an immuno-modulatory cell response as well. 
 
2.2.4. Neuroprotection vs. neurodegeneration: production of mediators 
Microglial cells are the source of an array of mediators that may either have a neurotoxic or 
neuprotective effect (Fig. I. 8). During brain development and in physiological conditions, microglia 
contributes to growth, functional maintenance and phenotypic development of neuronal cells, as well 
as to proliferation and growth of glial cells by producing neurotrophic factors, such as the glial cell line-
derived neurotrophic factor, basic fibroblast growth factor, brain-derived neurotrophic factor (BDNF), 
nerve growth factor and neurotrophins (Lindvall et al., 1994; Nakajima et al., 2001a). 
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Activation of microglia upon CNS injury has been considered as a detrimental event. This idea 
came from considering the inflammatory and cytotoxic phenotype acquired by LPS-stimulated 
microglia in cell-cultures as typical of activation (Schwartz et al., 2006; Hanisch and Kettenmann, 
2007). However, recent studies suggest that under pathological conditions, microglia exert 
neuroprotective functions through the production of neurotrophic molecules and by clearance of cell 
debris (Kitamura et al., 2009). In fact, microglial activation by an acute CNS injury intends to 
ameliorate primary tissue damage and promote repair. Thus, release of such mediators is a first step 
in creating an environment propitious to regeneration which involves the recruitment of phagocytic and 
neuronal precursor cells to the site of injury (Streit, 2002; Neumann et al., 2009). 
There is accumulating evidence suggesting a role for these mediators in the regeneration of brain 
tissue after injury. These include cytokines in a soluble form for auto- and paracrine signaling or 
membrane-associated for cell-to-cell interaction, and which participate in a multitude of biological 
processes by serving cellular communication. Indeed, several studies show that microglia protect 
neurons in damaged brain by secreting anti-inflammatory cytokines and growth factors like IL-10, 
TGF-β and BDNF (Streit, 2005). TGF-β appears to act as an autocrine mediator by regulating 
negatively inflammatory and immunoregulatory functions of activated microglia, such as suppresion of 
cytokine production and ROS formation (Suzumura et al., 1993). Also, pro-inflammatory cytokines, 
such as IL-1β, il-6 and TNF- α, can also be released to play a role in neuroprotection (Imai et al., 
2006). In fact, TNF-α released by activated microglia is suggested to induce expression of potent 
angiogenic factors that promote retinal neovascularization during post-ischemic inflammation (Yoshida 
et al., 2004). Also, injection of exogenous microglia itself protected CA1 pyramidal neurons against 
ischemia-induced neuronal degeneration possibly through a neurotrophin-dependent mechanism 
(Hayashi et al., 2006; Imai et al., 2006).  
Neuroprotection by microglia also involves their ability to uptake excitotoxic glutamate by 
expressing glutamate transporter 1 (Nakajima et al., 2001b). Interestingly activation of this transporter 
by glutamate leads to production of neurotrophic factors by microglia via PKC pathway (Liang et al., 
2010).  
In fact, microglia contribute to host defense and repair with immune cytokines acting as 
neurotrophic substances, protecting and promoting neurite growth during neurodevelopment and 
under most acute conditions. However, with intense activation, these cytokines and other mediators 
released by microglia can be very destructive leading to the establishment and maintenance of brain 
damage (Minghetti and Levi, 1998; Blaylock, 2004). Secretory components include proteinases, ROS 
and nitrogen intermediates, chemokines, pro-inflammatory cytokines and excitotoxins, such as 
glutamate (Banati et al., 1993). IL-1β and TNF-α are two pro-inflammatory cytokines, early and 
prominently produced by microglia upon activation, indicated to have a critical role in 
neuropathologies. Indeed, TNF-α lies at the beginning of a signal cascade that can lead to neuronal 
cell death. Also, this cytokine potentiates glutamate neurotoxicity and can stimulate the production of 
IL-1β, IL-6 and other cytotoxic cytokines (Lee et al., 1993; Chao and Hu, 1994). Thus, cytotoxic 
properties of microglia can be modulated by cytokines themselves. For example, while IFN-γ prime 
microglia to become activated producing reactive nitrogen intermediates and TNF-α, following LPS 
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treatment, (Meda et al., 1995), studies using organotypic hippocampal slice cultures demonstrated 
that they act neuroprotectively when pre-activated with IL-4 (Butovsky et al., 2006).  
NO is the mainly free radical produced by murine microglia upon activation by several stimulants 
like LPS (Tambuyzer et al., 2009). In co-cultures with neurons, microglia production of ROS lead to 
the reduction of neurite growth during brain development (Thery et al., 1991). Also, NO induces 
glutamate release from neurons that leads to NMDA receptors activation and consequent 
excitotoxicity (Brown, 2010). Years of research using LPS model of microglia activation, have shown 
that LPS acts on the specific microglial receptors TLR4 and Mac-1 triggering a signaling pathway that 
results in pro-inflammatory gene expression mediated by NF-κB activation and neuronal death (Loane 
and Byrnes, 2010).  
Microglia are also a source of matrix MMPs, namely MMP-2 and MMP-9 which expression can be 
induced by LPS stimulation. These enzymes have been shown to degrade components of the basal 
lamina, leading to the disruption of the BBB and thus, contributing to the neuroinflammatory response 
in many neurological diseases (Rosenberg, 2002).  
 
Fig. I. 8. Examples of mediators produced in neuroprotection and neurodegeneration. 
Microglia exert neuroprotective functions through the production of neurotrophic factors (NTFs) and by the 
clearance of cell debris, during brain development and under pathological conditions,. Also, they express a 
glutamate transporter (GLT-1) responsible for the uptake of excitotoxic glutamate. In certain conditions, activation 
of microglia can exert neurotoxic functions by producing nitric oxide (NO) that intertferes with neurite growth and 
contributes to the release of glutamate. Also, pro-inflammatory gene expression by nuclear factor (NF)-κB result 
in pro-inflammatory cytokines production, such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β. Release 
of these mediators contributes to excitotoxicity resulting in neuronal death. In addition, metalloproteinases 
(MMPs) are released leading to the disruption of the blood-brain barrier. 
 
Recalling the issue of the different states of activation of microglia and their corresponding 
functions, we can, in a very simplistic way, define these cells as anti-inflammatory M2 cells or pro-
inflammatory M1 cells. However, as already mentioned, microglia response to injury is complex and 
multifaceted. Nevertheless, it should be always kept in mind that microglia primary purpose is to limit 
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further damage and restore normal homeostasis, although excessive activation can cause secondary 
damage leading to aggravation of the pathological scenario. 
 
3. Microglia involvement in neurological diseases  
Microglia are involved with the onset and progression of the inflammatory response within the 
brain (Chew et al., 2006) so that unregulated response or over-activation of microglia can have 
disastrous neurotoxic consequences (Block and Hong, 2005). However, microglia may also exert 
neuroprotective functions in several pathological conditions. 
 
3.1. Acute vs. chronic neuroinflammation 
Within the context of the CNS, acute reactions occur as a response to limit neuronal damage, as 
already mentioned, and involve the activation of glial cells, a process also referred  as “reactive 
gliosis”, without BBB breakdown or concomitant leukocyte infiltration. Chronic inflammation is 
generally associated with a CNS disease context rather than CNS injury (Streit et al., 2004a). Since 
brain is not an immune privileged organ, as originally described, neurodegenerative diseases are 
characterized not only by local inflammation from resident cell types in the brain, but also by infiltration 
of peripheral immune cells. However, while infiltrating peripheral immune cells can represent a factor 
for neuronal toxicity, not always is associated with neurotoxicity, suggesting that local glial cells play a 
critical role in the inflammatory response (Block and Hong, 2005). Indeed, peripheral adaptive immune 
system has a key role in the defense of CNS against insults by the  production of cytokines that 
modulate microglial functions (Schwartz et al., 2006). Since infiltration of peripheral immune cells is 
restricted in the absence of infection or injury, CNS-resident cells such as microglia represent the first 
line of defense against invading pathogens and potentially provide innate immune signals leading to 
subsequent adaptive immune responses. These infection-causing microorganisms are recognized by 
TLRs and  trigger the release of pro-inflammatory cytokines, as well as the up-regulation of cell 
surface molecules involved in the initiation of adaptive immune responses to pathogens (Olson and 
Miller, 2004; Parkhurst and Gan, 2010).  
In acute CNS injury, microglial cells migrate towards the site of lesion where they exert their 
functional roles. However, whether these functions are pro-regenerative, like phagocytosis and 
neurotrophic factor production, or neurodegenerative, like the release of pro-inflammatory mediators, 
differs on the condition. Nevertheless, even though acute insult may trigger oxidative and nitrosative 
stress, it is typically short-lived and unlikely to be detrimental to long-term neuronal survival (Frank-
Cannon et al., 2009). 
In contrast, chronic activation is a long-standing and often self-perpetuating neuroinflammatory 
response that persists long after an initial injury or insult and is, therefore, an important component of 
the neurodegenerative diseases (Frank-Cannon et al., 2009). Microglia can become chronically 
activated by either a single, or multiple stimuli, resulting in cumulative neuronal loss (Lull and Block, 
2010). Neuronal damage triggers neighboring microglia activation and the production of pro-
inflammatory mediators that lead to more cellular death, representing an interminable cycle of 
progressive neuronal loss (McCarty, 2006). Neurodegenerative CNS disorders, including AD and 
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Parkinson’s disease (PD), are associated with chronic neuroinflammation and elevated levels of 
several cytokines. Therefore, rather than serving a protective role as does acute neuroinflammation, 
chronic neuroinflammation is most often detrimental and damaging to the nervous tissue (Frank-
Cannon et al., 2009). The mechanisms by which neuronal damage activates the chronic and 
deleterious microglial inflammatory response appear to involve a  combination of several factors 
released by neurons that produce multiple alterations in the extracellular matrix (Bonneh-Barkay and 
Wiley, 2009). For instance, recently, it was proposed that the interaction between high-mobility group 
box 1 (released from inflamed microglia and/or degenerating neurons) with microglial Mac1, sustain 
chronic inflammation and mediate chronic dopaminergic neurodegeneration, in PD. This, results from 
the activation of NF-κB pathway and NADPH (nicotinamide adenine dinucleotide phosphate) oxidase 
which leads to the production of multiple inflammatory and neurotoxic factors (Gao et al., 2011). 
Interestingly, several studies demonstrated that microglia can be activated by a pro-inflammatory 
stimulus in the absence of neuron damage, if the regulatory mechanisms that maintain the 
homeostasis and prevent microglia from becoming deleterious are deregulated. Therefore, excessive 
activation could only occur in response to a potent stimulus where these mechanisms are 
overwhelmed (Block and Hong, 2007). An alternative explanation is that microglia could become 
“primed” by a previous stimuli so that an additional insult results in an exaggerated and prolonged 
inflammatory response (Dilger and Johnson, 2008). Indeed, occurrence of nonspecific systemic 
infection or inflammation is associated with higher risks of prevalence of neurodegenerative diseases 
suggesting a crosstalk between systemic inflammation and microglia activation in the CNS (Perry et 
al., 2003; Perry et al., 2010). Also, the aging process may  serve as a "priming" stimulus for microglia 
and a secondary injury will amplify their response explaining the majority of neurodegenerative 
diseases in later life, such as PD (Block and Hong, 2007; Dilger and Johnson, 2008). 
Once again, polarization of microglial cells, which is determined by the environment, will also 
determine the response to different pathological conditions. M1 macrophages drive the pathogenesis 
of both types of disease through common mechanisms as well as through disease-specific 
mechanisms (Saijo and Glass, 2011). For instance, after spinal cord injury, microenvironment favors 
cytototxic M1 polarization with only a transient appearance of M2 macrophages, early after injury. 
Whether these cells retain some M2 characteristics, return to a resting, M0 state or remain mostly 
cytotoxic is still not known (David and Kroner, 2011). An opposite scenario is found during progression 
of gliomas. Wu and his colleagues (2010) demonstrated that glioma cancer stem cells, present in 
malignant gliomas, recruit and polarize the macrophages/microglia to become immunosuppressive. 
Recent information corroborates the view that TAMs are polarized M2 macrophages/microglia and 
therefore capable of participating in circuits that regulate tumor growth and progression, adaptative 
immunity, stroma formation and angiogenesis (Mantovani et al., 2002). However, the onset of gliomas 
has the contribution of M1 macrophages for the creation of a pro-inflammatory environment that is 
mutagenic and promotes growth (Saijo and Glass, 2011).  
In summary, although classical activation of microglia may lead to neurotoxicity, this response is 
essential for the defense from extracellular pathogenic organisms. Also, alternative activation, as 
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shown above, may have detrimental outcome. Therefore, an appropriate balance needs to be 
achieved between M1 and M2 polarization states 
From a therapeutic point of view, knowledge about production of specific forms of microglial 
activation could be the key in turning a pathogenic cell into a therapeutic modality. For instance, it was 
recently described that PS-containing liposomes can mimic the effects of apoptotic cells on 
phagocytes to induce the secretion of PGE2, and then shift microglia and macrophages from pro- to 
anti-inflammatory phenotype by an autocrine action of this growth factor (Wu and Nakanishi, 2011). 
 
3.2. Neonatal hyperbilirubinemia 
Bilirubin is the final product of heme degradation. At physiologic pH, bilirubin is insoluble in 
aqueous solution and binding to albumin is required for transportation from blood to the liver. After 
conjugation in the liver, it is excreted in bile (Kapitulnik, 2004). Presence of high levels of 
unconjugated bilirubin (UCB), a frequent condition in the neonatal period, may cause encephalopathy. 
Newborns produce bilirubin at a rate of more than twice the production in adults, because of an 
increased red blood cell turnover and an immature hepatic clearance (Ostrow et al., 2004). As a 
consequence, UCB levels may exceed the binding capacity of albumin and the “free”, unbound, 
bilirubin deposits in the skin and mucus membranes giving to the newborns a typical yellow coloration, 
called neonatal jaundice (Porter and Dennis, 2002). This temporary “physiologic” jaundice that usually 
resolves after the first week of life, may have neuroprotective effects if the concentrations of UCB are 
only slightly elevated, favoring the  antioxidant properties of the compound (Kapitulnik, 2004). More 
elevated concentrations that some infants manifest, may lead to the deposition of this pigment in 
selected regions of the brain, originating kernicterus and even death. Despite the severity of 
kernicterus, the prevalence of this condition is extremely low and what is turning to be important is the 
possible association between severe jaundice and long-term neurological defects (Brites, 2011). In 
fact, recent data shows an increased prevalence of mental disorders, like schizophrenia, and an 
affected cognitive ability in early adulthood (Newman and Maisels, 1990; Maimburg et al., 2008) with 
the neonatal jaundice condition. 
 
3.2.1. Molecular basis of microglial response to UCB 
Several cellular aspects are affected by UCB. These include alterations of cell morphology (Brito 
et al., 1996; Brito et al., 2000), disruption of plasma membrane integrity and functionality (Brito et al., 
2001; Brito et al., 2002; Rodrigues et al., 2002a; Rodrigues et al., 2002b), impairment of endocytosis 
(Silva et al., 2001a), inhibition of both DNA and protein synthesis (Greenfield and Majumdar, 1974; 
Yamada et al., 1977), as well as of protein phosphorylation (Hansen et al., 1996). It begins to be 
clarified the cellular functions that are mainly affected in different CNS cells and thus, in what extent 
each cell-dependent injury will contribute to the neurodevelopmental outcome of UCB 
encephalopathy.  
Susceptibility to UCB is dependent of both cell type and its differentiation state (Fig. I. 9). These 
differences are associated with distinct responses to UCB toxicity depending on the pathways 
involved.  In terms of cell type, neurons present a higher rate of cell death both by necrosis and 
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apoptosis whereas astrocytes reveal impaired glutamate uptake , as well as MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) metabolism (Silva et al., 2002). Inhibition of 
glutamate uptake results in its permanence in the synaptic cleft leading to NMDA-mediated 
excitotoxicity (Grojean et al., 2000). Neurons are more vulnerable to oxidative stress that astrocytes 
because of lower glutathione stores (Brito et al., 2008b). This oxidative injury comprises several 
alterations, like protein oxidation, lipid peroxidation and ROS formation (Brito et al., 2004). Also, there 
is a deregulation of the energy metabolism with collapse of the inner-mitochodrial membrane potential 
and ATP release (Vaz et al., 2010). Thus, although astrocytes are still affected by UCB, neurons are 
more susceptible to mechanisms leading to irreversible damage for which it could account a favored 
binding of UCB to neuronal cells and also a higher expression of efflux pumps on astrocytes (Silva et 
al., 2002). Exposure of astrocytes and microglia to UCB initiates an inflammatory response that 
involves TNF-α and IL-β pathways followed by mitogen-activated protein kinases and NF-κB signaling 
cascades culminating in the production of TNF-α and IL-β, accumulation of extracellular glutamate and 
consequent cell death (Fernandes et al., 2006; Gordo et al., 2006). Interestingly, this inflammatory 
response in microglia is preceded by a phagocytic phenotypes in which microglia attempt to restrain 
the extension of lesion. Only after prolonged exposure to UCB, microglia start releasing pro-
inflammatory mediators (Silva et al., 2010). Interestingly, levels of TNF-α and IL-β released by these 
cells are much higher than those secreted by astrocytes and even more if compared to neurons 
(Gordo et al., 2006). Microglia are, therefore, the most reactive cells to UCB and consequently may 
aggravate neurotoxicity.  
 
 
Fig. I. 9. General molecular mechanisms of unconjugated bilirubin (UCB)-induced neurotoxicity. 
UCB triggers several toxic-related molecular mechanisms in nerve cells. The vulnerability to the deleterious 
effects of UCB depends on the maturation stage so that it increases with days in vitro (DIV).  
 
Regarding the maturation stage of cells, it appears that the more immature cells are the higher 
vulnerability to UCB-mediated neurotoxicity is observed. Contributing to the susceptibility of immature 
nerve cells to UCB is the reduced expression of the multidrug resistance-associated protein 1 
transporter. This protein limits the accumulation of UCB within the cells by its active export and its 
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expression increases with cell differentiation (Falcão et al., 2007a). Accordingly, younger astrocytes 
are more vulnerable to cell death, glutamate efflux and inflammatory response than older ones (Falcão 
et al., 2005).  
Exposure of neural precursors to UCB leads to a decrease in viability and neurogenesis of 
proliferating cells as well as to an increase in cellular dysfunction of differentiating cells. Thus, these 
deleterious effects of UCB in the developing CNS may compromise performance of brain in later life. 
Indeed, exposure of immature neurons to UCB leads to reduction of both neurite extension and 
number of nodes, effects that are increasingly perpetuated along cell differentiation and exacerbated if 
exposed later to an inflammatory agent (Falcão et al., 2007b). UCB also interferes with axonal growth, 
cone area and spine formation (Fernandes et al., 2009), further confirming that its effects in the 
developing brain may lead to decreased synaptic connectivity, which may underlie the emergence of 
neurodegenerative diseases. Furthermore, by damaging olygodendrocytes, UCB may compromise 
myelin biogenesis and repair and, consequently, axonal function. The microenvironment influences 
cellular response to UCB, particularly of microglial cells. Recent findings revealed that conditioned 
media derived from UCB-treated astrocytes reduce microglial inflammatory reaction and cell death, 
probably in an attempt to constrain microglial over-activation. Furthermore, damaged neurons may 
signal microglial clearance functions by releasing soluble factors, but they can also overstimulate their 
inflammatory potential, by promoting the release of IL-6 and NO, as well as MMP-9 activation, leading 
to their demise (Silva et al., 2011). The outcome of nerve cell response to UCB is summarized in Fig. 
I. 8. 
 
Fig. I. 10. Contribution of each cell-dependent injury to the general outcome of unconjugated bilirubin 
(UCB) toxicity.  
Unconjugated bilirubin (UCB) has evidenced toxicity for all the represented cell types. These effects  may 
culminate in nerve cell death, both by apoptosis and necrosis. Based on Brites, 2011. 
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Concerning therapeutic strategies for preventing UCB-induce neurotoxicity, several compounds 
have already been tested with beneficial results. Since bile salts can stimulate biliary excretion of 
organic anions, including bilirubin in rats (Cuperus et al., 2009), it was suggested that administration of 
such compounds could be relevant for the treatment of unconjugated hyperbilirubinemia. Indeed, dally 
administration of ursodeoxycholic acid, induced a rapid and sustained decrease in plasma UCB 
concentrations in Gunn rats by stimulation of UCB turnover and its fecal disposal (Cuperus et al., 
2009). Furthermore, this hydrophilic bile salt was shown to inhibit mitochondrial membrane instability 
and release of cytochrome c, preventing apoptosis (Silva et al., 2001b; Rodrigues et al., 2002a). 
Recent studies demonstrated that the antioxidant compound glycoursodeoxycholic acid (GUDCA) and 
the immunomodulatory cytokine IL-10 are capable of suppressing UCB pro-inflammatory proprieties 
(Fernandes et al., 2007; Fernandes and Brites, 2009). Additionally, GUDCA significantly prevented 
UCB-induced oxidative stress, metabolic alterations, like disruption of glutathione redox status and cell 
demise in neurons (Brito et al., 2008a; Vaz et al., 2010). Regarding microglial cells, both GUDCA and 
IL-10 reduced accumulation of extracellular glutamate and counteracted the impairment of neurite 
outgrowth and ramification, as well as cell death in UCB-treated neurons. However, only GUDCA 
prevented the UCB synaptotoxicity from occurring (Silva, 2010),  pointing out this molecule as a 
promising therapeutic agent in the management of neonatal hyperbilirubinemia. 
 
4. Aims 
This work was initially elaborated to evaluate the effect of UCB on eithet basal microglial migration 
or stimulated microglia, by using ATP or S100B, well-known chemoattractants of these cells. Once 
GUDCA has already revealed to have antioxidant, immunomodulatory and anti-apoptotic properties, 
we also aimed to assess its modulation ability on the effects produced by UCB on microglial migration. 
When facing the variations between results obtained in different microglia cultures, we 
hypothesized that we were dealing with a variety of cell phenotypes, which under “stressed” conditions 
would respond differently to UCB interaction. This led us to also characterize microglial phenotypes in 
cultures during time in vitro.  
 
Therefore, the aims of the present thesis encompass: 
 
1) Chemotaxis assays to evaluate microglial migration, in what concerns: (i) the potential of 
“free” unbound UCB as a chemotactic agent; (ii) the capacity of migration of UCB-treated 
microglia; and (iii) the modulation capability of GUDCA on UCB-treated microglia; 
 
2) Characterization of microglial cultures over time in vitro to identify microglial phenotypes. 
 
 
 
 
 
 
  
 
27 
 
II. MATERIALS AND METHODS
 
 
 
 
29 
II. MATERIALS AND METHODS 
 
 
1. Materials 
 
1.1. Chemicals 
Dulbecco’s modified Eagle’s medium-Ham’s F12 medium (DMEM-Ham’s F-12), fetal bovine 
serum (FBS), L-glutamine, sodium pyruvate and nonessential aminoacids were purchased from 
Biochrom AG (Berlin, Germany); fibronectin, antibiotic-antimycotic solution (Ab/Am) (20X), human 
serum albumin (HSA; fraction V, fatty acid free), bovine serum albumin, ATP, Hoechst 33258 dye, 
biotinylated, fluorescent latex beads 1 μm (2.5%) and were from Sigma Chemical Co. (St. Louis, MO). 
UCB was also obtained from Sigma and purified according to the method of McDonagh and Assisi 
(1972). Glycoursodeoxycholic acid (GUDCA) (minimum 96% pure) was obtained from Calbiochem 
(Darmstadt, Germany); (Darmstadt, Germany); Trypsin/Ethylenediamine tetraacetic acid (EDTA) 
solution (0.25% trypsin, 1 mM EDTA in Hank’s balanced salt solution) was purchased from Invitrogen 
Corporation™ (Carlsbad, CA, USA); DPX mountant for microscopy was obtained from BDH Prolabo 
(Poole, UK); L-glutamic acid kit, Triton X-100 were obtained from Roche Diagnostics Deutschland 
GmbH (Mannhein, Germany); S100B was kindly provided by Dr. Cláudio Gomes, from Instituto de 
Tecnologia Química e Biológica, Universidade Nova de Lisboa. 
All the other chemicals were of analytical grade and were purchased from Sigma or Merck. 
 
1.2. Antibodies 
Rabbit anti-p65 NF-κB subunit was from Santa Cruz Biotechnology® (Santa Cruz, CA, USA) and 
goat anti-ionized calcium-binding adaptor molecule 1 (Iba1) was from Abcam (Cambridge, UK); mouse 
anti-glial fibrillary acidic protein (GFAP) was from Novocastra (Newcastle Tyne, UK) and rabbit anti-
microtubule-associated protein 2 (MAP-2) was from Covance (Princeton, NJ, USA); secondary 
antibody chicken Alexa Fluor 594 anti-goat IgG was purchased from Invitrogen Corporation (Carlsbad, 
CA) and horse FITC-labeled anti-mouse was from Vector Laboratories (Burlingame, CA, USA); goat 
anti-rabbit cyanine dye (CY)2, goat anti-mouse CY3 and anti-rabbit horseradish peroxidase 
conjugated anti-IgG were acquired from GE Healthcare (Chalfont St. Giles, UK). 
 
1.3. Equipment 
A 48-well microchemotaxis chamber and polycarbonate track-etch membranes with 
polyvinylpyrrolidone (PVP) treatment were purchased from Neuro Probe, Inc (Gaithersburg, MD, 
USA). Leica DFC490 camera adapted to an AxioSkope® microscope were from Carl Zeiss, Inc., 
(North America). 
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2. Methods 
 
2.1. Primary culture of microglia 
Animal care followed the recommendations of European Convention for the Protection of 
Vertebrate Animals Used for Experimental and other Scientific Purposes (Council Directive 
86/609/EEC) and National Law 1005/92 (rules for protection of experimental animals). All animal 
procedures were approved by the Institutional Animal Care and Use Committee. Every effort was 
made to minimize the number of animals used and their suffering. 
Mixed glial cultures were prepared from 1-to-2 day-old CD1 mice as previously described 
(McCarthy and de Vellis, 1980), with minor modifications (Gordo et al., 2006). Cells (4 x 10
5 
cells/cm
2
) 
were plated on uncoated 12-well tissue culture plates (with 18 mm coverslips) or 75-cm
2
 culture flasks 
in culture medium (DMEM-Ham’s F-12 medium supplemented with 2 mM L-glutamine, 1 mM sodium 
pyruvate, nonessential amino acids 1X, 10% FBS, and 1% antibiotic-antimycotic solution) and 
maintained at 37ºC in a humidified atmosphere of 5% CO2. 
Microglia were isolated as previously described by Saura et al. (2003). Briefly, after 21 days in 
culture, microglia were obtained by mild trypsinization with a trypsin-EDTA solution diluted 1:3 in 
DMEM-Ham’s F12 for 45 to 60 min. The trypsinization resulted in detachment of an upper layer of 
cells containing all the astrocytes, whereas the microglia remained attached to the bottom of the well. 
The medium containing detached cells was removed and replaced with initial mixed glial-conditioned 
medium. The use of 21 days in vitro (DIV) cells intents to achieve the maximal yield and purity of the 
cultures. In fact, astrocyte contamination was less than 2%, as assessed by immunocytochemical 
staining with a primary antibody against GFAP followed by a species-specific fluorescent-labeled 
secondary antibody and also there was no neuron contamination, as assessed by 
immunocytochemical staining with a primary antibody against MAP-2 followed by a species-specific 
fluorescent-labeled secondary antibody (Silva et al., 2010).  
 
2.2. Migration Assay 
Twenty-four hours after microglia trypsinization, attached cells on uncoated 75-cm
2
 flasks were 
subjected to different treatments. After these incubations, isolated microglia were recovered by a 10-
min incubation with pure trypsin-EDTA solution with subtle scratching and vigorous pipetting. 
Chemotaxis assays were performed using this cell suspension (Fig. II.1). 
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Fig. II. 1. Schematic representation of the experimental model for chemotaxis assays.  
Mixed glial cultures were prepared from 1-to-2 day-old CD1 mice and plated on 75-cm
2
 culture flasks in culture 
medium. After 21 days in vitro (DIV), isolated microglia was obtained by mild trypsinization. At 1 DIV, cells were 
subjected to the different treatments. After 24 h-incubations, isolated microglia were recovered by tripsinization 
followed by subtle scratching and vigorous pipetting. Chemotaxis assays were performed in using this cell 
suspension.  
 
2.2.1. Cell treatments 
Microglial cells were incubated with DMEM-Ham’s F12 without (control) or with 50 μM UCB, in the 
presence of 100 µM HSA for 24 h, at 37ºC. In parallel experiments, cells were pre-incubated with 50 
μM GUDCA (from a 5 mM stock solution), 1 h prior to UCB addition.  
To study the role of free, unbound UCB (fUCB) as a chemoattractor, microglia were incubated with 
DMEM-Ham’s F12 only.  
The UCB stock solution (10 mM) was prepared in 0.1 M NaOH immediately before use and the pH 
of the incubation medium was restored to 7.4 by addition of equal amounts of 0.1 M HCl. All the 
experiments with UCB were performed under light protection to avoid photodegradation. 
 
2.2.2. Establishment of the microchemotaxis assay 
Implementation of the microchemotaxis assay was an especially difficult and time-consuming 
process. We have originally adopted the protocol reported by Färber et al. (2008) but, after several 
attempts and failures, several modifications were made in order to achieve optimal results (Fig. II. 2).  
Cell migration assays were performed in a 48-well microchemotaxis chamber. The bottom wells of 
the Boyden chamber were loaded with solutions described in Table II.1. A PVP-treated polycarbonate 
filter (8 μm pore size) was washed with 0.02 N acetic acid to remove PVP treatment and coated with 
10 mg/ml fibronectin in PBS overnight as described by Honda et al. (2001) and installed in the 
microchemotaxis chamber. 
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Fig. II. 2. Representative steps of the chemotaxis assay.  
a-b. Microchemotaxis chamber is disassembled (thumbnuts, top plate and gasket are removed); c. solutions of 
potential chemoattractants are added to the lower wells (in the bottom plate); d. A coated filter is placed on top of 
bottom chamber; e-f. Chamber is assembled (gasket and top plate are placed over the filter and thumbnuts are 
tightened); g. Cellular suspension is applied into the upper wells (in the top plate)  h. Microchemotaxis chamber is 
prepared; i. Chamber is left for 40 min at room temperature and then incubated for 3h at 37ºC and 5% CO
2
; j. 
Chamber is disassembled and, with cells facing up on the filter, a cut is made on the top right corner of the filter 
for orientation; k. Non-migrated cells are removed with a cotton swab soaked in PBS; l. Cells are fixated with 
methanol; m. Filter is placed with cell-side up on a disposable lint-free towel for air-drying; n. For staining, Giemsa 
solution is infiltrated under the filter with cell-side down; o. Filter is rinsed with distilled water; p. Filter is placed on 
a glass slide for air-drying; q. Filter is mounted with Entellan between slide and coverglass and wells are marked 
on the slide.  
 
Table II. 1. Solutions loaded to the bottom wells of the microchemotaxis chamber. 
 
 
 
After the incubation procedures, described in 2.2.1., microglia were suspended in serum-free 
DMEM-Ham’s F-12 and 50 μL of cell suspension was placed into each top well (3 x 10
4
 cells/well). 
40 min resting at room temperature
3 h incubating at 37 ºC, 5% CO2
Condition Solution 
Vehicle DMEM-Ham’s F-12 
Described chemoattractants 
ATP (300, 100 and 10 µM) 
S100B  (1 µM) 
Potential chemoattractants fUCB (70 and 140 nM) 
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The Boyden chamber was left at room temperature for 40 min, in order for cells to settle and to 
improve even distribution on the filter as described by Miller and Stella (2009), and then placed in a 
CO2 incubator at 37°C for 3 hours. The filter was removed and cells on the top side of the filter were 
wiped off with cotton-tipped swabs soaked in PBS. Filter was then fixed with methanol and stained 
with freshly prepared and filtered 10% Giemsa in PBS according to Chen (2004). Image of one 
microscopic field (original magnification: 100X) were acquired per well using a Leica DFC490 camera 
adapted to an AxioSkope® microscope and the number of cells was counted. On each experiment at 
least three wells were sampled per condition. 
 
2.3. Microglia phenotypic characterization 
After mild trypsinization, attached cells on uncoated 18-mm coverslips were maintained at 37ºC in 
a humidified atmosphere of 5% CO2 until reaching 2, 10, 13 or 18 DIV for culture characterization. 
Culture medium was replaced every 4 days (Fig. II. 3). 
 
 
Fig. II. 3. Schematic representation of the experimental model for culture characterization.   
Mixed glial cultures were prepared from 1-to-2 day-old CD1 and plated on uncoated 12-well tissue culture plates 
(with 18 mm coverslips) in culture medium. After 21 days in vitro (DIV), isolated microglia was obtained by mild 
trypsinization and cultures were maintained for 18 DIV. At 2, 10, 13 and 18 DIV, we evaluated the parameters 
indicated above, for culture characterization. NF-κB, nuclear factor-κB. 
 
2.3.1. Morphological Analysis 
For morphological analysis, cells with different DIV were fixed for 20 min with freshly prepared 4% 
(w/v) paraformaldehyde in PBS and a standard immunocytochemical technique was performed using 
a primary antibody raised against Iba-1 (goat, 1:500) and a secondary Alexa Fluor 594 chicken anti-
goat antibody (1:200). To identify the total number of cells, microglial nuclei were stained with Hoechst 
33258 dye. Fluorescence was visualized using a Leica DFC490 camera adapted to an AxioSkope® 
microscope. Pairs of U.V. and green-fluorescence images of ten random microscopic fields (original 
magnification: 400X) were acquired per sample. The number of round and ramified microglia was 
counted to determine the percentage of both morphological types at each DIV. 
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2.3.2. Detection of NF-κB activation 
For immunofluorescence detection of NF-κB nuclear translocation, cells were fixed as described 
above and a standard indirect immunocytochemical technique was carried out using a polyclonal 
rabbit anti-p65 NF-κB subunit antibody (1:200) as the primary antibody and a anti-rabbit Cy2 as the 
secondary antibody (1:1000). Microglial nuclei were stained with Hoechst 33258 dye Fluorescence 
was visualized using a Leica DFC490 camera adapted to an AxioSkope® microscope. Pairs of U.V. 
and green-fluorescence images of ten random microscopic fields (original magnification: 400X) were 
acquired per sample. NF-κB positive nuclei (identified by localization of the NF-κB p65 subunit staining 
exclusively at the nucleus) and total cells were counted to determine the percentage of NF-κB-positive 
nuclei at each DIV. 
 
2.3.3. Assessment of microglial phagocytic properties 
To evaluate the phagocytic capacity of the primary microglial cultures, cells with different DIV were 
incubated with 0.0025% (w/w) 1 μm fluorescent latex beads for 75 min at 37ºC and fixed with freshly 
prepared 4% (w/v) paraformaldehyde in PBS.  Microglial nuclei were counterstained with Hoechst 
33258 dye. Fluorescence was visualized using a Leica DFC490 camera adapted to an AxioSkope® 
microscope. U.V. and green fluorescence images of ten random microscopic fields (original 
magnification: 400X) were acquired per sample. The number of ingested beads per cell and total cells 
was counted to determine the percentage of phagocytic cells and the mean number of ingested beads 
per cell. 
 
3. Statistical Analysis 
Results of, at least, three different experiments were expressed as mean ±S.E.M. Significant 
differences between two groups were determined by the two-tailed t-test performed on the basis of 
equal and unequal variance as appropriate. Comparison of more than two groups was done by 
ANOVA followed by Dunnett's multiple comparison test or Tukeys multiple comparison test as appropriate. 
Statistical analysis weres performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA, 
USA) Statistical significance was considered for a p value less than 0.05. 
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III. RESULTS 
 
 
Microglia are known to play crucial roles in the development and course of neurodegeneration. 
Due to the immunostimulatory effects of UCB and microglia activation (Fernandes et al., 2004; Gordo 
et al., 2006) it is expected that microglia will be chemoattracted by soluble factors released by 
astrocytes or neurons upon exposure to UCB, or even to UCB itself. Extracellular ATP is the main 
stimulus for activation and early motility of microglia following several injuries (Kurpius et al., 2007; 
Samuels et al., 2010). In fact, as previously introduced, microglia can transform into mobile 
phagocytes and rapidly accumulate at sites of neuronal injury, promoting clearance of dead and dying 
cells and thereby helping to limit secondary injury during hyperbilirubinemia. Recent findings 
evidenced a switch of this chemotactic response to ATP in activated, or proinflammatory, microglia. 
Specifically, in LPS-activated microglia, ATP induced process retraction and repulsive migration, 
effects that are opposite to those seen in unstimulated cells (Gyoneva et al., 2009). Moreover, S100B 
protein, extremely elevated in the aging brain and in several pathological conditions, also seems to 
stimulate microglia migration (Bianchi et al., 2011). Thus, in this section it will be evaluated the effects 
of UCB on microglia migration in the absence or presence of these chemoattractants. GUDCA acid 
will be the compound assessed as a promising therapeutics to modulate microglia migration, once our 
lab has demonstrated that GUDCA as immunomodulatory properties, among others (Fernandes et al., 
2007; Fernandes and Brites, 2009) 
 
1. Assessment of microglial chemotaxis to “free” UCB , evaluation of UCB-treated cells ability 
to migrate, and evaluation of GUDCA as modulator of microglial migration  
This task aimed to evaluate the role of UCB in microglia migration during neonatal 
hyperbilirubinemia. Microglia chemotaxis is usually evaluated by the scratch assay (Yuskaitis and 
Jope, 2009) or by transwell /Boyden Chamber assays (Takayama and Ueda, 2005; McHugh et al., 
2010). We decided to use only the Boyden Chamber, once the scratch assay did not previously 
proven to be reproducible in our model. 
 
1.1. Evaluation of the chemoattractive potential of UCB  
To explore whether microglial cells showed an increased ability to migrate when stimulated by 
UCB we selected two different concentrations of “free” UCB (70 nM and 140 nM) that previously 
revealed to produce neurotoxic effects in vitro (Brito et al., 2008b). Different concentrations of ATP (10 
and 300 µM) were used to evaluate the most effective as chemoattractant and to allow the 
interpretation of UCB effects. 
As shown in Fig. III. 1, 300 μM ATP strongly stimulated migration as compared to the lower 
concentration of 10 μM, which did not cause any effect in the number of migrated cells comparatively 
to the vehicle. Moreover, both concentrations of fUCB showed no effect on microglia migration ability. 
These results demonstrate that, in these conditions, in our model, fUCB does not act as a chemotactic 
agent for these cells indicating an additional prejudicial effect to the UCB-induced neurotoxicity. In 
fact, instead of promoting the clearance of dead neurons, by “calling” microglia to the site of injury, 
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fUCB revealed total inability to attract these cells. To notice that the assays revealed a great variability 
between cultures, probably due to phenotypical diversity of microglia cultures, and therefore, this topic 
deserves further investigation. Nevertheless, we thought that could be interesting to evaluate if 
microglia migratory behavior would be altered by exposure to UCB, namely when in the presence of 
factors usually release by damaged cells, such as ATP and S100B.  
 
 
Fig. III. 1. Free, unbound, unconjugated bilirubin (fUCB) do not induce chemotaxis of microglial cells in 
the Boyden chamber assay.  
Microglia migration ability was assessed in the absence (vehicle) and in the presence of fUCB (70 and 140 nM) or 
ATP (10 and 300 µM). Data are shown as the mean ± SEM of at least three independent experiments. Statistical 
analysis was performed by one-way ANOVA followed by Dunnett's multiple comparison test. ***p<0.001 vs. 
vehicle 
 
1.2. Evaluation of microglia migration ability when treated with UCB 
Although migration toward pathological area is the first critical step in microglia engagement 
during the central CNS injury, we believe that during certain pathological scenarios, these cells might 
be affected in such a way that they do not accumulate at the lesion site. Although immunosuppressive 
effect of UCB on chemotaxis of peripheral immune cells has already been described (Vetvicka et al., 
1991), the influence of UCB stimulation in this property was never investigated in the brain immune 
cells, microglia. Thus, we evaluated the migratory ability of UCB-treated cells after a 24 h incubation 
period.  
Exposure of microglial cells to UCB led to a great loss of their migration ability, as represented in 
Fig. III. 2. We have observed a reduction of approximately 40% in the number of migrated cells 
comparatively to cells that were not exposed to the compound (control). Again, we wonder whether we 
had been able to reproduce microglia phenotypes from culture to culture as suggested by the 
variability of the results, and so, we will surely address this point again in the future. 
To assess whether the effect was maintained in the presence of chemotatic agents, we used 300 
µM ATP that we previously demonstrated to induce such attraction, as well as 1 µM of S100B, recently 
indicated to stimulate microglia migration. Interestingly, microglia previously incubated with UCB 
revealed decay in its migration ability to such compounds (Fig. III. 3) pointing to UCB damage to 
microglial cells. As in the previous section, UCB diminished microglia chemotaxis ability in more than 
50%. Again, this reduced response in UCB-treated microglia, even in the presence of ATP and 
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S100B, is very interesting in revealing a new pathophysiological mechanism that UCB may have in 
neurological injury produced during kernicterus. Therefore, to confirm this immunosupressive effects 
of UCB on microglia migration, microglia phenotype should be next characterized and reproduced 
between experiments. In fact, we were surprised to observe a higher number of control cells migrating 
to the vehicle than when stimulated with ATP, suggesting a repulsive effect of this compound (data not 
shown), an effect already described for LPS-activated microglial cells. 
 
 
Fig. III. 2. Unconjugated bilirubin (UCB) exerts immunosuppressive effect on microglia migration. 
The migration assay was performed with non-treated (control) or UCB-treated (50 µM) microglia, as described in 
Materials and Methods.  Data are shown as the mean ± SEM of at least three independent experiments. 
Statistical analysis was performed by a two-tailed t test. *p<0.05 vs.control. 
 
 
Fig. III. 3. Immunosuppressive effects of unconjugated bilirubin (UCB) are maintained even in the 
presence of the chemotactic compounds ATP and S100B. 
The migration assay was performed with non-treated (control) or UCB-treated microglia in the presence of ATP 
(300 µM) or S100B (1 µM), as described in Materials and Methods. Data are shown as the mean ± SEM of at 
least three independent experiments. Statistical analysis was performed by a two-tailed t test. *p<0.05 vs.control.  
 
1.3. Evaluation of GUDCA efficacy in modulating migration of UCB-treated microglia  
We observed intriguingly effects of GUDCA on non-treated or UCB-treated microglial cells. Both in 
the presence of ATP or DMEM-Ham’s F12 alone, this bile acid appears to have almost the same 
effect as UCB (Fig. III. 4). In contrast, when microglial cells were treated with a combination of UCB 
and GUDCA the results revealed a marked increased stimulation in microglia migration ability, with the 
number of migrated cells largely surpassing those obtained in all other conditions. This novel 
modulation by GUDCA may have very important implications in the early stages of UCB-induced 
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neurotoxicity. This consideration comes from the observation that migratory response decreased in 
the presence of ATP and S100B, i.e. when the neural cells release such compounds in response to 
UCB-cytotoxicity. As before, we will have to make proof of concept of such data in the future. 
 
 
Fig. III. 4. Glycoursodeoxycholic acid (GUDCA) stimulates cell migration of unconjugated bilirubin (UCB)-
treated microglia which is maintained in the presence of ATP and abolished in the presence of S100B. 
The migration assay was performed in the absence and in the presence of ATP (300 µM) or S100B (1 µM), as 
described in Materials and Methods. Cells were not treated (control) and treated with 50 µM UCB or 50 µM 
GUDCA, alone or in association Results are shown as fold change ± SEM compared with UCB or GUDCA 
normalized to control values of three independent experiments. Statistical analysis was performed by one-way 
ANOVA followed by Tukeys multiple comparison test.  
 
1.4. Critical analysis of the results  
We realized that the great variability between experiments as well as the reduced number of 
migrated cells in all assays may have made impossible to achieve statistical significance in some 
cases where the results clearly pointed to differences, and therefore, may have compromised the 
results achieved. We thought that this could be a consequence of the existence of multiple microglia 
phenotypes, whose representation might be distinct from experiment to experiment. Also, cells could 
be previously activated as a result of the “stress” caused by the isolation procedure. This idea of an 
reactive microglia is reinforced by the inability of ATP to stimulate migration of these cells is several 
experiments. Indeed, it was demonstrated that this compound can induce process retraction and 
repulsive migration in LPS-activated microglial cells (Gyoneva et al., 2009). Also, even in the activated 
state, microglial cells from the same culture can have different phenotypes and respond differently to a 
same stimulus. Furthermore, if microglial cells were indeed activated by the isolation procedure, a 
subsequent stimulus, like UCB, might have led to their over-activation. Based on that, we decided not 
to pursue further the experiments without investigating which microglia phenotype we were dealing 
with. 
 
2. Microglial activation profile: Influence of the days in culture  
Microglia cultures are a common system employed to explore aspects of microglia phenotype and 
function. The majority of experiments to study microglia biology are conducted in isolated microglia 
recently obtained, assuming that they present the same phenotype as the one we would encounter in 
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their physiological microenvironment. However, a recent study with microglia cultures from rat ventral 
midbrain demonstrated that the experimental procedures to obtain primary cultures change initial 
activation status of microglial cells so that they remain in the activated state for several days after the 
isolation process (Cristóvão et al., 2010). Therefore, when evaluating microglia reactivity to potential 
toxic compounds one must consider that this reactivity may change depending on the microglia 
phenotype. 
In this section, we established primary cultures of microglial cells from whole brain of newborn 
mice and we have evaluated the changes in the activation profile of these cells over time in culture. 
 
2.1. Microglia morphology changes with the days in culture 
Modification of microglial morphology is one of the hallmarks of its activation profile and has been 
widely used to categorize different activation states (Kim and de Vellis, 2005; Chew et al., 2006). For 
this reason, we used immunocytochemistry to assess the morphology of microglia from cultures kept 
for 2, 10, 13, and 18 DIV. More than 98% of the cells in culture were immunopositive for the microglia 
marker Iba1 (Fig. III. 5A). Amoeboid and ramified cells were counted and our results revealed a 
gradual increase in the number of ramified cells along time in vitro till the 13 DIV (Fig. III. 5B), followed 
by a slight decrease at 18 DIV, indicating that microglia acquires a more “resting” phenotype at 13 DIV 
in culture. In fact, ramified cells increased from 2 to 13 DIV, where they achieved the value of 83.2 ± 
5.1%, thus with a majority of cells showing a morphology indicative of surveillant microglia. If we look 
to the number of cells with amoeboid morphology, more characteristic of reactive microglia, we 
observed a decrease from 31.6 ± 0.6% at 2 DIV to 30.0 ± 5.2% at 10 DIV, achieving the minimum 
representation of 15.9 ± 5.1% at 13 DIV. Notice that the cultures at 18 DIV showed, again, a novel 
increase in amoeboid cells (22.7 ± 9%) (Fig. III. 5B). Branched cells from these cultures were typically 
unipolar or bipolar. The expression and localization of Iba1 in microglial cells has also changed during 
time in vitro. Initially Iba1 besides being localized in the cytoplasm and nucleus, could also be 
observed in lamellipodia and membrane ruffles. After 18 DIV, expression became weak and localized 
throughout the microglial processes, with exceptional cases in which Iba1 expression was 
preferentially perinuclear (Fig. III. 5A). Moreover, nucleus became more elongated and some rod-
shaped nucleus morphology could be seen (Fig. III. 5Aa-d) together with a lower cell density, therefore 
suggesting loss of cell functionality. 
 
2.2. Activation state of microglial changes with the days in culture 
Microglial cells play key immune-related duties, intervening by producing anti-inflammatory 
compounds and trophic factors, by phagocytizing non-functional tissue, as well as by releasing 
cytokines. Production of several cytokines during microglial activation process is associated with the 
activation of the inducible transcription factor NF-κB. To evaluate the functional behavior of primary 
microglial cultures, we investigated NF-κB transactivation at the same time points used for analyzing 
morphological changes. We evaluated the localization, either cytoplasmic or nuclear, of p65 NF-κB 
subunit by immunocytochemistry (Fig. III. 6A). NF-κB positive and negative nuclei were counted and 
we observed maximum levels of NF-κB activation at 2 DIV (14.6 ± 3.3%), thus confirming the previous 
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Fig. III. 5. Microglia morphology evaluation point to 13 days in vitro (DIV) cultures as the most suitable for 
studies of reactivity 
A. Microglial cell cultures from mouse cerebral cortex were labeled with Iba1 at different (DIV). Morphological 
changes occur both in cytoplasm and nucleus of microglial cells (a – d). B. Quantification of amoeboid (arrow in 
A) and ramified microglial cells (arrowhead in A) at different DIV. The minimum value of amoeboid morphology 
was observed after 13 DIV, with the majority of cells showing the ramified morphology characteristic of non-
reactive microglia. Data are mean ± SEM from at least four independent experiments performed in duplicate. 
Statistical analysis was performed by one-way ANOVA followed by Tukey's multiple comparison test. **p<0,01 
and ***p<0.001, comparing the number of amoeboid cells to the number of ramified cells. Scale bar = 50 µm; 
insets scale bar = 5 µm.  
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Fig. III. 6. Microglial cells at 13 in vitro (DIV) show the lowest levels of nuclear factor-kappaB (NF-κB) 
activation. 
A. Microglial cells at different DIV were immunostained with an antibody against p65 NF-κB subunit. B. 
Quantification of NF-kB positive (arrow in A) and negative nuclei (arrowhead in A) of microglial cells at different 
DIV indicate that the less activation is achieved after 13 DIV.  Data are mean ± SEM from at least four 
independent experiments performed in duplicate. Statistical analysis was performed by one-way ANOVA followed 
by Tukey's multiple comparison test. *p<0.05 vs. 2 DIV. Scale bar = 50 µm.  
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results showed maximum levels of NF-κB activation at 2 DIV (14.6 ± 3.3%), thus confirming the 
previous results obtained for morphology and reinforcing that cells are still highly reactive after 2 DIV. 
NF-κB translocation into the nucleus achieved the minimum levels at 13 and 18 DIV with less than 5% 
of the cells evidencing NF-κB activation (Fig. III. 6B). 
To further characterize the state of activation of these cultures over time in vitro, we then 
evaluated the phagocytic capability of primary microglial cells at early and late time points after plating 
(Fig. III. 7A). Phagocytosis achieved the lowest values at 10 DIV whereas cultures with 13 DIV 
showed the best responsiveness to the latex beads (Fig. III. 7B).  
 
Fig. III. 7: Microglia phagocytic phenotype achieved maximum capability at 13 days in vitro (DIV). 
A. Microglial cells at different DIV were incubated with 1 µm fluorescent latex beads as described in Materials and 
methods. B. Quantification of bright, punctuated fluorescent cells at different DIV. Data are shown as the mean ± 
SEM of at least four independent experiments performed in triplicated. Statistical analysis was performed by one-
way ANOVA followed by Tukey's multiple comparison test. Scale bar = 20 µm.  
 
Interestingly, and in agreement to what we have been pointing lately, we observed a wide diversity 
in both in terms of number of phagocytic cells (data not shown) and in terms of the number of beads 
ingested per cell at each DIV. Taking this into account, cultures with 13 DIV show the most equitable 
representation of the distinct phagocytic behaviors (Fig. III. 8). 
 
Table III. 1. Microglial cultures with 13 days in vitro (DIV) present the best representation of the 
phagocytic phenotypes variability. 
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≥10 6.0 0.1 1.2 1.6 
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In this work we showed that exposure to UCB leads to a reduction of microglia ability to migrate, 
even in the presence of chemoattractants such as ATP and S100B. Even in the absence of albumin, 
fUCB has no direct effect on chemotactic response of microglia. Interestingly, when incubated with a 
combination of UCB plus GUDCA, in contrast with either one alone, microglia develops a significant 
increase in its migration ability. Microglia have shown different phenotypes according with the time of 
culture, and the 13 DIV revealed to be the best time to obtain the microglia morphology of the “resting” 
state, together with the less NF-κB translocation to the nucleus and the most equilibrated 
representation of phagocytic phenotypes, indicating that microglia response to insult should be 
evaluated at 13 DIV in our model.  
The first response of microglial cells to an insult is their rapid accumulation at the site of lesion. 
This is a consequence of migration and proliferation of these cells regulated by numerous factors 
released at the local. Indeed, it is hypothesized that a halo of ATP in micromolar range exists even in 
the steady state and levels of 80–100 μM may be released by astrocytes (Lambert et al., 2010). This 
purine has been extensively reported as a chemoattractant of microglia as it induces membrane 
ruffling and chemokinesis of these cells in Boyden chamber assays (Honda et al., 2001), and also 
leads to activation and migration of microglia in vivo (Samuels et al., 2010). Here, we provide another 
evidence for ATP role as a chemoattractive compound and confirm 300 µM as an effective 
concentration for stimulation of microglia migration, as already described by Miller and Stella (2009). 
Furthermore, with this study we started to unveil the role of UCB in the migratory ability of microglial 
cells, never performed previously. The results we obtained, evidence that fUCB has no 
chemoattractant effect on these cells. Therefore, data suggest that, during neonatal 
hyperbilirubinemia, distant microglia are not recruited to the site of neuronal injury by fUCB, what may 
additionally damage neurons and glial cells. This is not without precedent since it was demonstrated 
that UCB inhibits chemotaxis of human polymorphonuclear leukocytes upon stimulation with 
chemotactic agents (Miler et al., 1981; Vetvicka et al., 1991). Moreover, a recent study showed that 
one day after intracerebral hemorrhage, there was an increased neutrophil infiltration associated with 
UCB whereas an opposite effect was seen for microglia that was present in a reduced number at the 
site of lesion (Loftspring et al., 2011).  
Microglia can either decrease or enhance its migratory ability after exposure to stimuli. Therefore, 
we evaluated how microglia behaves after treatment to UCB when exposed to vehicle and to ATP or 
S100B. In these conditions it seems that UCB is responsible for immunosuppressive effects on 
microglia chemotaxis. Only a few papers have previously addressed this issue for other compounds. 
Our results point to an UCB-mediated reduction in microglia ability to migrate. Moreover, this 
immunosuppressive effect was maintained in the presence of ATP or S100B. Previous results have 
shown that 2-chloro-N(6)-(3-iodobenzyl)-5'-N-methylcarbamoyl-4'-thioadenosine (LJ529), a selective 
A3AR agonist, prevented the infiltration/migration of microglia and monocytes after middle cerebral 
artery occlusion and reperfusion, or after LPS injection into the corpus callosum. Moreover, using a 
mouse BV-2 microglial-like cell model, Fraga and his co-workers (2011) demonstrated that the 
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exogenous cannabinoids Delta-9-tetrahydroca nnabinol (THC) and CP55940 exerted a concentration-
related reduction in the migration of BV-2 cells. Effects of UCB at the level of membranes (Brito et al., 
2004) may trigger the redistribution of receptors, thus changing microglia motility response. 
 A direct interaction of UCB molecules or UCB-albumin complexes may be a primary cause of the 
observed effects. The binding to cell membranes might significantly alter the cell membrane properties 
and thus change the normal functions of the membrane structures. This mechanism might explain the 
changes in metabolism of cells by blocking the transmembrane transfer of signals leading to various 
cell functions. Indeed, the changes in receptor expression or other, even more delicate, properties of 
the plasma membrane can significantly influence the migration pattern of lymphoid cells (Vetvicka et 
al., 1991). In addition, we now think that microglia phenotype may respond differently to UCB stimulus, 
as the results of section 2 have shown, indicating that further studies must be carried out to investigate 
whether the immunosuppressive effects exerted by UCB in the presence of albumin are also observed 
in other less “stressed” microglia phenotypes. 
GUDCA is the major product of ursodeoxycholic acid catabolism (Rudolph et al., 2002) and has 
demonstrated protective effects against other UCB-induced deleterious effects. Recent reports have 
indicated potential benefits for GUDCA at preventing UCB-induced protein oxidation, lipid 
peroxidation, impairment of glutathione homeostasis and neuron cell death (Brito et al., 2008a) or 
mitochondrial respiratory chain dysfunction by UCB, and restoration of cellular antioxidant potential 
(Vaz et al., 2010). Based on these facts, we next investigated whether this compound revealed ability 
to abrogate the immunosuppressive effect of UCB on migration of microglial cells. Never described, it 
seems that microglia treatment with the combination of GUDCA and UCB triggers on microglia an 
increased migration ability, which, although reduced, is still observed in the presence of ATP. 
However, in the presence of S100B, GUDCA and UCB lose their synergistic effect. This, again, may 
be a result of changes in receptor expression or localization. For instance, GUDCA exposure could 
prevent some essential receptors from stop being expressed or internalized after exposure to UCB. 
More importantly,  these results show that GUDCA can be used as a therapeutical compound but only 
as a preventive measure or in an initial phase of UCB-induced injury, before astrocytes begin to 
release S100B. 
Phenotypical characterization of mciroglial cultures showed that cells recently isolated still present 
features of activation and therefore the response to subsequent chemotactic stimuli can be masked. 
Indeed, we observed that control cells were less able to migrate to ATP that to the vehicle, an effect 
already described after LPS stimulation. The repulsive effect is mediated by the upregulation of A2AR 
with a coincident downregulation of P2Y12R and depend on the breakdown of ATP to adenosine 
(Gyoneva et al., 2009). Also, this 2 DIV microglia showed to behave differently from culture to culture 
and to not be adequately responsive to chemotactic agents. These results led us to consider that the 
microglia phenotype may determine the microglia responsiveness we obtained with cells at 2 DIV in 
culture. Therefore, we decided to not proceed with further experiments until we could understand how 
differently microglia may behave according to the days in vitro after isolated. Indeed, the majority of 
experiments performed to understand microglia biology has been performed in recently isolated 
microglia, assuming that cells show the same phenotype as the one encountered for microglia in its 
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natural physiologic microenvironment. However, a recent study with microglia cultures from rat ventral 
midbrain demonstrated that the experimental procedures to obtain primary cultures change initial 
activation status of microglial cells so that they remain in the activated state for several days after the 
isolation process (Cristóvão et al., 2010).  
Thus we next characterized primary microglia cultures from the mouse cortex, conserved in 
culture for 2, 10, 13 and 18 DIV. The method used to obtain microglial cells is based on mild 
trypsinization of mixed glial cultures that showed to result in the detachment of an upper layer of 
astrocytes whereas the microglial cells remain attached to the bottom of culture support. This isolation 
method was indicated to be simple and reproducible, but more important it allows a higher yield than 
the shaking method (Saura et al., 2003). Characterization was based on morphological evaluation, 
assessment of NF-κB activation and phagocytic ability.  
Despite plasticity in morphology of activated microglia, it is well accepted that they have an 
amoeboid shape whereas “resting” microglia present a ramified morphology with small cell bodies and 
thin processes (Kreutzberg, 1996; Tambuyzer et al., 2009). Also, a previous study has demonstrated 
the correlation between morphology and cell activation state by evaluating the expression of CD68, a 
marker for activated microglia (Cristóvão et al., 2010). In this work, we observed that the number of 
cells with a large and amoeboid shape, characteristic of an activated or reactive microglia (Nakajima 
and Kohsaka, 2004), was at maximum levels at 2 DIV microglia, decreasing thereafter as a result of 
increased number of cells with a ramified morphology, a feature of the “resting” state. These “process-
bearing” cells showed, more commonly, a uni- or bipolar morphology, probably due to the method of 
isolation of these cells, although this same pattern has already been observed in microglia obtained by 
the shaking method (Giulian and Baker, 1986). As expected, we observed changes in the morphology 
of the nucleus, which started with a round shape and evolved to a thin, elongated morphology. An 
intriguing result was the appearance of cells with rod-shaped nucleus at 18 DIV. This type of cells, 
commonly called as rod cells, have been associated to chronically inflamed cerebral cortex (Hof and 
Mobbs, 2009). Indeed, they have been described in acutely dementing processes like lead 
encephalopathy, subacute sclerosing panencephalitis (SSPE), and various forms of viral encephalitis, 
including HIV-1 (Graeber, 2010). These descriptions led us to question at what extent 18 DIV ramified 
morphology may be considered as being in a resting state or, in contrast, in a senescent state. In fact, 
the expression of Iba1, which is directly related to microglial activation, was observed to change with 
the time in vitro, becoming weaker, as previously indicated to quiescent ramified microglia (Imai et al., 
1996; Ohsawa et al., 2000).  
Morphological changes occurred in parallel with a decrease in the transactivation of NF-κB. It is 
well known that this transcription factor is found throughout the cytoplasm, translocating to the nucleus 
upon activation triggering the transcription of target genes, such as the pro-inflammatory cytokines 
(O'Neill and Kaltschmidt, 1997). Therefore, maximal activation of NF-κB two days after isolation is 
consistent with an inflammatory phenotype that shifts to a surveillant state along with the time in 
culture. These observations are in accordance with the work of Fujita and colleagues (1996) who  
suggest that the isolation process constitutes a sufficient stimulus to induce microglia activation, an 
issue also recently addressed by others (Cristóvão et al., 2010). Both studies revealed that microglial 
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cells display characteristics of activated microglia, even before any stimulation, determined by the 
isolation process. 
Higher phagocytic ability seemed to be directly related with the days in culture, from 13 DIV 
forward. For that may account the isolation of microglial cells from their microenvironment and from 
the normal constrains that influence their phenotype and role in the survival of neurons (Ransohoff 
and Perry, 2009). Also, phagocytic activity of microglia seems to increase with  age (Luo et al., 2010) 
once microglial cells might acquire features resembling activation as a result of impaired cell functions 
(Streit and Xue, 2009). An alternative explanation is that microglia could generate an inflammatory 
response followed by a phagocytic one or even that two different subpopulations exist engaging the 
two types of response, being the inflammatory subpopulation firstly extinguished and substituted by a 
rather paghocytic one. Indeed, we recently demonstrated a similar, although inverse, microglial 
response to UCB stimulation (Silva et al., 2010). This hypothesis of different subpopulations had 
already been considered by Giulian and Baker (1986) and more recently different types of 
macrophage activation, referred as macrophage polarization have been described (Miron et al., 2011).  
Therefore, we may have in culture cells with distinct polarizations accounting for the differing 
responses and thus explaining the variability we observed. Indeed, distinct phenotypes can have 
divergent effects in response to CNS injury (Kigerl et al., 2009; David and Kroner, 2011). We can also 
not discard that beads we used may not be incorporated by microglia being instead increasingly 
located at the plasma membrane by adhesion processes, and thus we should use in the future other 
available particles that only fluoresce upon lysosome intervention (Strunnikova et al., 2009) to 
corroborate the results here obtained. 
 
Collectively our results indicate that UCB may have immunosuppressive effects on microglia 
migration, that GUDCA induces cell migration when combined to UCB, and that isolated cells 
maintained in culture for 13 DIV apparently show the best behavior for studies intended to evaluate 
microglia reactivity to UCB, and probably to other stimuli. Moreover, we have demonstrated that 
different phenotypes, probably with distinct polarization states, respond differently to the same 
stimulus. Thus, future studies should consider evaluating microglia phenotypes before cells are used 
in the evaluation of UCB effects. Moreover, recent studies have pointed out that some compounds 
may be used to either lead to unstimulated or stimulated microglia (Klegeris et al., 2008; Labuzek et 
al., 2010; Ribes et al., 2010) producing prevalent microglia phenotype homology important to 
decrease the variability of results between experiments, when using different microglia cultures. 
 
 
Futures perspectives 
This work allowed us to further understand the complexity of phenotypes that a single culture of 
microglia can comprehend. This opens a new window for further studies about the different responses 
that each subtype can engage upon a stimulus. Also, it led us to reconsider the choice of markers for 
microglial characterization. In injured CNS, macrophages and microglia in different regions of the brain 
show differences in morphology and surface markers. Resting microglia can be distinguished from 
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activated macrophages/microglia by their low CD45 expression. However, in the injured CNS, they 
cannot be distinguished neither by their morphology, nor by surface markers. Nevertheless, other 
markers are variably expressed by different subpopulations like CD16, CD23 and iNOS in M1, or 
arginase 1, CD206 and mannose receptor in M2. We believe that flow cytometer will add substantial 
information in acquiring a detailed description of the distinct phenotypes exhibited by cells when 
isolated or maintained in culture for different duration. Moreover, other markers that can be more 
accurate to evaluate phagocytic ability will certainly add on phenotypic-related stimulation of 
phagocytosis. In fact, because classical fluorescent beads may not adequately assess this property 
once we cannot be sure about their location unless tridimensional images are acquired. To overcome 
this problem, it would be of interest to use particles that can detect both phagocytosis and endocytosis 
to discriminate endocytosed from adherent extracellular particles like pHrodo™ E. coli BioParticles. 
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